Globus Medical (GMED) 10-K 26 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Billions, except Share data, unless otherwise specified	Dec. 31, 2014	Jan. 31, 2015	Jun. 30, 2014
DEI [Abstract]
Entity Registrant Name	GLOBUS MEDICAL INC
Entity Central Index Key	1237831
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		94,761,428
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$1.60

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
ASSETS
Cash and cash equivalents	$82,265	$89,962
Restricted cash	23,370	0
Short-term marketable securities	146,439	148,962
Accounts receivable, net of allowances of $1,647 and $1,581, respectively	75,430	62,414
Inventories	90,945	70,350
Prepaid expenses and other current assets	5,742	5,080
Income taxes receivable	5,772	2,723
Deferred income taxes	40,062	37,317
Total current assets	470,025	416,808
Property and equipment, net of accumulated depreciation of $118,544 and $99,910	69,475	64,150
Long-term marketable securities	75,347	36,528
Intangible assets, net	34,529	29,537
Goodwill	53,196	18,372
Other assets	975	909
Total assets	703,547	566,304
LIABILITIES AND EQUITY
Accounts payable	15,904	10,073
Accounts payable to related-party	5,359	2,656
Accrued expenses	61,499	51,125
Income taxes payable	569	2,358
Business acquisition liabilities, current	6,081	1,730
Total current liabilities	89,412	67,942
Business acquisition liabilities, net of current portion	20,195	15,528
Deferred income taxes	5,166	6,385
Other liabilities	3,320	4,089
Total liabilities	118,093	93,944
Commitments and contingencies (Note 14)
Equity:
Additional paid-in capital	175,242	153,987
Accumulated other comprehensive loss	-1,657	-1,009
Retained earnings	411,774	319,289
Total equity	585,454	472,360
Total liabilities and equity	703,547	566,304
Class A Common
Equity:
Common stock	71	66
Class B Common
Equity:
Common stock	$24	$27

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Current Assets:
Allowance for doubtful accounts	$1,647	$1,581
Equity:
Common stock, shares issued	94,705,743	93,442,753
Common stock, shares outstanding	94,705,743	93,442,753
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$118,544	$99,910
Class A Common
Equity:
Common stock, par value (in usd per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued	70,828,187	66,065,197
Common stock, shares outstanding	70,828,187	66,065,197
Class B Common
Equity:
Common stock, par value (in usd per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	275,000,000	275,000,000
Common stock, shares issued	23,877,556	27,377,556
Common stock, shares outstanding	23,877,556	27,377,556

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Sales	$474,371	$434,459	$385,994
Cost of goods sold	110,857	100,343	75,199
Gross profit	363,514	334,116	310,795
Operating expenses:
Research and development	31,687	26,870	27,926
Selling, general and administrative	187,798	182,518	168,862
Provision for litigation litigation loss/(income)	5,667	23,055	-786
Total operating expenses	225,152	232,443	196,002
Operating income	138,362	101,673	114,793
Other income/(expense), net	280	328	-140
Interest income, net	805	467	80
Foreign currency transaction loss	-899	-804	-220
Other income	374	665	0
Income before income taxes	138,642	102,001	114,653
Income tax provision	46,157	33,389	40,822
Net income	$92,485	$68,612	$73,831
Earnings per share:
Basic	$0.98	$0.74	$0.82
Diluted	$0.97	$0.73	$0.80
Weighted average shares outstanding:
Basic	94,227	92,647	89,608
Dilutive stock options	1,230	1,545	2,600
Diluted	95,457	94,192	92,208
Anti-dilutive stock equivalents excluded from weighted average calculation	1,666	1,975	2,383

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net income	$92,485	$68,612	$73,831
Other comprehensive income/(loss):
Unrealized gain on marketable securities, net of tax	-96	32	0
Change in accumulated foreign currency translation gain/(loss)	-552	-274	435
Total other comprehensive income/(loss)	-648	-242	435
Comprehensive income	$91,837	$68,370	$74,266

Consolidated_Statements_of_Equ

Consolidated Statements of Equity (USD $)	Total	Convertible Preferred Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Retained Earnings	Class A Common	Class B Common	Class C Common	Pre IPO	Pre IPO	Pre IPO	Pre IPO	In Conjunction with IPO	In Conjunction with IPO	In Conjunction with IPO	In Conjunction with IPO	In Conjunction with IPO	In Conjunction with IPO	Post IPO
In Thousands, except Share data, unless otherwise specified	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	Common Stock	Common Stock	Common Stock	Convertible Preferred Stock	Class A Common	Class B Common	Class C Common	USD ($)	Convertible Preferred Stock	Additional Paid-in Capital	Class A Common	Class B Common	Class C Common	Class A Common
						USD ($)	USD ($)	USD ($)	USD ($)	Common Stock	Common Stock	Common Stock		USD ($)	USD ($)	Common Stock	Common Stock	Common Stock	Common Stock
										USD ($)	USD ($)					USD ($)	USD ($)	USD ($)
Total stockholders' equity, beginning of period at Dec. 31, 2011	$282,476	$51	$106,708	($1,202)	$176,846	$8	$65	$0
Balance, Shares at Dec. 31, 2011		50,691,000				7,453,000	65,018,000	58,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	4,635		4,635
Exercise of stock options (shares)	1,061,000	0				898,000	147,000	16,000
Exercise of stock options	1,504	0	1,503			1	0	0
Tax benefit related to nonqualified stock options excercised	2,661		2,661
Conversion of stock, converted (shares)									0		-690,000	0		-50,691,000			-37,097,000	-74,000
Conversion of stock, amount converted								0	0		-1			-51			-37	0
Conversion of stock, issued (shares)										690,000						52,768,000
Conversion of stock, amount issued										1			0		36	52
Issuance of common stock from IPO, net of expenses (shares)						2,083,000
Issuance of common stock from IPO, net of expenses	20,960		20,958			2
Comprehensive income	74,266			435	73,831
Total stockholders' equity, end of period at Dec. 31, 2012	386,502	0	136,501	-767	250,677	64	27	0
Balance, Shares at Dec. 31, 2012		0				63,892,000	27,378,000	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	5,177		5,177
Exercise of stock options (shares)	2,173,000					2,173,000
Exercise of stock options	7,555		7,553			2
Tax benefit related to nonqualified stock options excercised	4,756		4,756
Comprehensive income	68,370			-242	68,612
Total stockholders' equity, end of period at Dec. 31, 2013	472,360	0	153,987	-1,009	319,289	66	27	0
Balance, Shares at Dec. 31, 2013		0				66,065,000	27,378,000	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	7,111		7,111
Exercise of stock options (shares)	1,263,000					1,263,000
Exercise of stock options	9,738		9,736			2
Tax benefit related to nonqualified stock options excercised	4,408		4,408
Conversion of stock, converted (shares)							-3,500,000
Conversion of stock, amount converted							-3
Conversion of stock, issued (shares)																			3,500,000
Conversion of stock, amount issued						3
Comprehensive income	91,837			-648	92,485
Total stockholders' equity, end of period at Dec. 31, 2014	$585,454	$0	$175,242	($1,657)	$411,774	$71	$24	$0
Balance, Shares at Dec. 31, 2014		0				70,828,000	23,878,000	0

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income	$92,485	$68,612	$73,831
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	21,754	19,397	18,108
Amortization of premium on marketable securities	2,680	2,358	0
Provision for excess and obsolete inventories	6,962	8,212	6,119
Stock-based compensation	7,111	5,177	4,635
Allowance for doubtful accounts	318	693	363
Change in deferred income taxes	-4,379	-14,858	-6,079
(Increase) decrease in:
Restricted cash	-23,370	0	0
Accounts receivable	-12,667	-9,612	-6,886
Inventories	-18,001	-16,678	-20,541
Prepaid expenses and other assets	-249	-2,955	-117
Increase (decrease) in:
Accounts payable	4,628	1,840	3,048
Accounts payable to related party	2,703	100	1,378
Accrued expenses and other liabilities	4,018	26,963	4,208
Income taxes payable/receivable	-4,821	4,222	-1,548
Net cash provided by operating activities	79,172	93,471	76,519
Cash flows from investing activities:
Purchases of marketable securities	-251,422	-240,892	0
Maturities of marketable securities	184,567	40,560	0
Sales of marketable securities	27,737	13,637	0
Purchases of property and equipment	-24,754	-23,680	-24,684
Acquisition of businesses	-36,128	-16,775	-6,031
Net cash used in investing activities	-100,000	-227,150	-30,715
Cash flows from financing activities:
Payment of business acquisition liabilities	-1,200	-1,300	-1,100
Net proceeds from initial public offering	0	0	20,960
Net proceeds from issuance of common stock	9,738	7,555	1,504
Excess tax benefit related to nonqualified stock options	4,408	4,756	2,661
Net cash provided by/(used in) financing activities	12,946	11,011	24,025
Effect of foreign exchange rate on cash	185	230	-97
Net increase/(decrease) in cash and cash equivalents	-7,697	-122,438	69,732
Cash and cash equivalents, beginning of period	89,962	212,400	142,668
Cash and cash equivalents, end of period	82,265	89,962	212,400
Supplemental disclosures of cash flow information:
Interest paid	32	96	63
Income taxes paid	$51,096	$38,719	$44,875

BACKGROUND_AND_SUMMARY_OF_SIGN

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Background and Summary of Significant Accounting Policies	BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	(a) The Company
	Globus Medical, Inc. and its subsidiaries is a medical device company focused exclusively on the design, development and commercialization of musculoskeletal implants. We are currently focused on implants that promote healing in patients with spine disorders. We are an engineering-driven company with a history of rapidly developing and commercializing advanced products and procedures that assist surgeons in effectively treating their patients, respond to evolving surgeon needs and address new treatment options. Since our inception in 2003, we have launched over 130 products and offer a product portfolio addressing a broad array of spinal pathologies.
	We are headquartered in Audubon, Pennsylvania and market and sell our products through our exclusive sales force in the United States, Europe, India, South Africa, Australia, South America and the Middle East. The sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.
	The terms the “Company,” “Globus,” “we,” “us” and “our” refer to Globus Medical, Inc. and, where applicable, our consolidated subsidiaries.
	(b) Basis of Presentation
	The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for financial statements and with the instructions to Form 10-K and Article 10 of Regulation S-X.
	Certain reclassifications have been made to prior period statements to conform to the current period presentation.
	(c) Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Globus and its wholly owned subsidiaries. Our consolidation policy requires the consolidation of entities where a controlling financial interest is held. All intercompany balances and transactions are eliminated in consolidation.
	(d) Use of Estimates
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.
	Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, provision for excess and obsolete inventory, useful lives of assets, the outcome of litigation, and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.
	(e) Foreign Currency Translation
	The functional currency of our foreign subsidiaries is their local currency. Assets and liabilities of the foreign subsidiaries are translated at the period end currency exchange rate and revenues and expenses are translated at an average currency exchange rate for the period. The resulting foreign currency translation gains and losses are included as a component of accumulated other comprehensive income. Gains and losses arising from intercompany foreign transactions are included in other income/(expense) on the consolidated statement of operations. We recognized foreign exchange transaction losses in other income/(expense) of $0.9 million, $0.8 million, and $0.2 million for the years ended December 31, 2014, 2013, and 2012, respectively.
	(f) Cash and Cash Equivalents
	Cash and cash equivalents include cash on hand and all highly liquid investments with a maturity of three months or less when purchased.
	(g) Restricted Cash
	In December 2014, we set aside $23.4 million in cash for the payment of a portion of the Synthes and Bianco litigations. We classified this cash as restricted, as the amount was placed in escrow to be used for payment of the litigation obligations, should we not be successful with our appeals. See “Note 14. Commitments and Contingencies” below for more details regarding these litigations.
	(h) Accounts Receivable and Allowance for Doubtful Accounts
	The majority of our accounts receivable is composed of amounts due from hospitals. We carry our accounts receivable at cost less an allowance for doubtful accounts. On a regular basis, we evaluate our accounts receivable and estimate an allowance for doubtful accounts, as needed, based on various factors such as our customers’ current credit conditions, length of time past due, and the general economy as a whole. Receivables are written off against the allowance when they are deemed uncollectible.
	(i) Concentrations of Credit Risk
	Financial instruments, which potentially subject us to concentrations of credit risk, are primarily cash and cash equivalents and accounts receivable. Concentrations of credit risk with respect to accounts receivable are limited due to the large number of entities comprising our customer base. We perform ongoing credit evaluations of our customers and generally do not require collateral.
	There was no customer that accounted for 10% or more of sales for the years ended December 31, 2014, 2013, and 2012, respectively.
	(j) Marketable Securities
	Our marketable securities include municipal bonds, corporate debt securities, commercial paper, securities of U.S. government-sponsored agencies and asset-backed securities, and are classified as available-for-sale as of December 31, 2014. Available-for-sale securities are recorded at fair value in both short-term and long-term marketable securities on our consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of accumulated other comprehensive income on our consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of our marketable securities are determined on a specific identification basis. Realized gains and losses, along with interest income and the amortization/accretion of premiums/discounts are included as a component of other income, net, on our consolidated statements of income. Interest receivable is recorded as a component of prepaid expenses and other current assets on our consolidated balance sheets.
	We maintain a portfolio of various holdings, types and maturities, though most of the securities in our portfolio could be liquidated at minimal cost at any time. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is considered to be other-than-temporary, the loss will be recognized in our consolidated statement of income in the period the determination is made.
	(k) Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The majority of our inventories are finished goods as we mainly utilize third-party suppliers to source our products. We periodically evaluate the carrying value of our inventories in relation to our estimated forecast of product demand, which takes into consideration the estimated life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a reserve for such excess inventories.
	(l) Property and Equipment
	Property and equipment are recorded at cost less accumulated depreciation. Additions or improvements are capitalized, while repairs and maintenance are expensed as incurred. Depreciation and amortization are provided using the straight-line method over the related useful lives of the assets.
	When assets are sold or otherwise disposed of, the related property, equipment, and accumulated depreciation amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.
	(m) Goodwill and Intangible Assets
	Goodwill represents the excess purchase price over the fair values of the identifiable assets acquired less the liabilities assumed. Goodwill is tested for impairment at a minimum on an annual basis. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount, to the fair value of the reporting unit. The fair values are estimated using an income and discounted cash flow approach. For the year ended December 31, 2014, we performed a qualitative test for impairment as permitted under Financial Accounting Standards Board (“FASB”) authoritative guidance. During the years ended December 31, 2014, 2013 and 2012, we did not record any impairment charges related to goodwill.
	Intangible assets consist of purchased in-process research and development (“IPR&D”), supplier network, patents, customer relationships and non-compete agreements. Intangible assets with finite useful lives are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from one to seventeen years. Intangible assets are tested for impairment annually or whenever events or circumstances indicate that a carrying amount of an asset (asset group) may not be recoverable. If impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset. Fair value is generally determined using a discounted future cash flow analysis.
	IPR&D has an indefinite life and is not amortized until completion of the project at which time the IPR&D becomes an amortizable asset. If the related project is not completed in a timely manner, we may have an impairment related to the IPR&D, calculated as the excess of the asset’s carrying value over its fair value.
	We completed our annual qualitative indefinite lived intangible asset impairment review in the fourth quarter of 2014 and determined that our intangible assets were not impaired.
	(n) Impairment of Long-Lived Assets
	We periodically evaluate the recoverability of the carrying amount of long-lived assets, which include property and equipment, as well as whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be fully recoverable. An impairment is assessed when the undiscounted future cash flows from the use and eventual disposition of an asset group are less than its carrying value. If impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset group. Our fair value methodology is based on quoted market prices, if available. If quoted market prices are not available, an estimate of fair value is made based on prices of similar assets or other valuation techniques including present value techniques. We reviewed our long-lived assets over the course of 2014 and 2013 and recorded an immaterial impairment charge as a component of cost of goods sold during 2013; there was no impairment of our long-lived assets during 2014.
	(o) Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, product delivery has occurred, pricing is fixed or determinable, and collection is reasonably assured. A significant portion of our revenue is generated from consigned inventory maintained at hospitals or with sales representatives. For these products, revenue is recognized at the time the product is used or implanted. For all other transactions, we recognize revenue when title to the goods and risk of loss transfer to customers, provided there are no remaining performance obligations that will affect the customer’s final acceptance of the sale. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold.
	(p) Research and Development
	Research and development costs are expensed as incurred. Research and development costs include salaries, employee benefits, supplies, consulting services, clinical services and clinical trial costs, and facilities costs. Costs incurred in obtaining technology licenses and patents are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.
	(q) Stock-Based Compensation
	The cost for employee and non-employee director awards is measured at the grant date based on the fair value of the award. The fair value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service period (generally the vesting period of the equity award). Awards issued to non-employees are recorded at their fair value as determined in accordance with authoritative guidance, and are periodically revalued as the awards vest and are recognized as expense over the requisite service period.
	The determination of the fair value of stock options is made utilizing the Black-Scholes option-pricing model which is affected by our stock price and a number of assumptions, including expected volatility, expected term, risk-free interest rate and expected dividends. The expected volatility is based upon the historical volatility of a public company peer group over the most recent period commensurate with the estimated expected term of the stock options. The expected term of the stock options is determined utilizing the simplified method given the limited extent of our historical data. The risk-free interest rate assumption is based on observed interest rates of U.S. Treasury securities appropriate for the expected terms of the stock options. The dividend yield assumption is based on the history and expectation of no dividend payouts.
	(r) Income Taxes
	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which such items are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is established to offset any deferred tax assets if, based upon available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	Significant judgment is required in determining income tax provisions and in evaluating tax positions. We will establish additional provisions for income taxes when, despite the belief that tax positions are fully supportable, there remain certain positions that do not meet the minimum probability threshold that a tax position is more likely than not to be sustained upon examination by the taxing authority. In the normal course of business, we and our subsidiaries are examined by various federal, state, and foreign tax authorities. We regularly assess the potential outcomes of these examinations and any future examinations for the current or prior years in determining the adequacy of the provision for income taxes. We periodically assess the likelihood and amount of potential adjustments and adjust the income tax provision, the current tax liability, and deferred taxes in the period in which the facts that give rise to a revision become known.
	(r) Fair Value of Financial Instruments
	As of December 31, 2014, the carrying values of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature. We classify our financial assets and liabilities that are measured at fair value into one of the three categories based upon inputs used to determine fair value. See “Note 5. Fair Value Measurements” below for more details regarding inputs and classifications.
	(s) Advertising Expense
	We expense advertising costs as they are incurred. Advertising expense was $0.5 million, $0.5 million and $0.4 million, for the years ended December 31, 2014, 2013, and 2012, respectively.
	(t) Legal Costs
	We expense legal costs related to loss contingencies as incurred.
	(u) Medical Device Excise Tax
	Effective as of January 1, 2013, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively “PPACA”) imposed a medical device excise tax (“MDET”) of 2.3% on any entity that manufactures or imports certain medical devices offered for sale in the United States. We account for the MDET as a component of our cost of goods sold. For the years ended December 31, 2014 and 2013, we recognized expenses of $7.1 million and $7.2 million, respectively.
	(v) Recently Issued Accounting Pronouncements
	In May 2014, the FASB and the International Accounting Standards Board released a standard on the recognition of revenue from contracts with customers that is designed to create greater comparability for financial statement users across industries and jurisdictions. Under the new standard, an entity will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the payment to which the entity expects to be entitled in exchange for those goods or services. The standard also will require enhanced disclosures and provide more comprehensive guidance for transactions such as service revenue and contract modifications. The standard will take effect for public companies for annual reporting periods beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. We are currently evaluating the impact of the new standard on our financial position, results of operations and disclosures.

ACQUISTIONS

ACQUISTIONS	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Business Acquisitions	ACQUISITIONS
	On October 23, 2014, we entered into an equity interest purchase agreement with Transplant Technologies of Texas, Ltd. (“TTOT”), an allograft tissue processor located in San Antonio, Texas, pursuant to which we acquired 100% of the equity interests for $36.1 million. In addition to the initial purchase price, we may be obligated to make milestone payments of up to $15.0 million over the next three years based primarily on sales thresholds from the product lines we acquired.
	TTOT was privately held and provides human tissue products including bone allografts, biomaterials, and soft tissue products for spine, orthopedics, sports medicine, dental, and wound care markets and represents a key step in fulfilling our strategy of building a broad business in regenerative biologics. While we currently partner with third party suppliers for our existing allograft products, the acquisition of TTOT will expand our suite of regenerative biologics products. We believe this acquisition will also improve our capabilities for the development of new and innovative human allograft tissue products in the future.
	We accounted for the acquisition under the purchase method of accounting, and as a result, recorded goodwill of $34.8 million. The results of operations of TTOT have been included in our results of operations from the date of acquisition. Prior-period results have not been restated and pro forma supplemental financial information is not provided as the impact of the TTOT acquisition is immaterial to the operating results for the years ended December 31, 2014 and December 31, 2013. Amounts recognized for assets acquired and liabilities assumed are based on preliminary purchase price allocations and on certain management judgments. These preliminary allocations are based on an analysis of the estimated fair values of assets acquired and liabilities assumed, including identifiable tangible and intangible assets, and estimates of the useful lives of tangible and amortizable intangible assets. The final purchase price allocations will be completed after we finalize our third-party appraisal, review all available data, and complete our own internal assessments. We expect to complete our final purchase price allocations by the end of March 2015. Any additional adjustments resulting from finalization of the purchase price allocations for TTOT will affect the amount assigned to goodwill.
	As of December 31, 2014, we recorded the following preliminary purchase price allocation for the identifiable tangible and intangible assets and liabilities of TTOT:
	(In thousands)
	Consideration:
	Cash paid at closing	$	36,128
	Contingent consideration	11,300			(1)
	Fair value of consideration	$	47,428
	Identifiable assets acquired and liabilities assumed:
	Inventory	$	9,599
	Supplier network	3,800
	Customer relationships	1,600
	Accounts receivable	1,529
	Equipment	518
	Trade names	300
	Other assets	292
	Accounts payable and accrued expenses	(5,034		)
	Total identifiable net assets	12,604
	Goodwill	34,824
	Total allocated purchase price	$	47,428
	-1	The contingent consideration relates to the achievement of certain sales milestones. As of December 31, 2014, the aggregate, undiscounted amount of contingent consideration that we could pay related to the acquisitions ranges from zero to $15.0 million (see “Note 5. Fair Value Measurements” below).
	On December 23, 2013, we entered into an asset purchase agreement with a small robotics development company, pursuant to which we acquired substantially all of its assets for $16.8 million. In addition to the initial purchase price, we may be obligated to make a milestone payment and revenue sharing payments based upon a percentage of net sales of certain products based on the intellectual property we acquired in the transaction. The acquired company was privately held and is focused on developing a next generation surgical robotic positioning platform for spine, brain and therapeutic markets. The technology is intended to enable surgeons to perform minimally invasive and percutaneous surgical procedures with greater accuracy, safety and reproducibility than is currently available. We accounted for this acquisition under the purchase method of accounting, and as a result, recorded goodwill of $3.0 million. The table below represents the valuation of the assets acquired and liabilities assumed as part of this 2013 purchase:
	(In thousands)
	Identifiable intangible assets:
	In-process research & development	$	20,460
	Non-compete agreements	20
	Contingent consideration	(6,704		)	(2)
	Total identifiable net assets	13,776
	Goodwill	2,999
	Net assets acquired	$	16,775
	-2	The contingent consideration relates to the achievement of certain regulatory milestones and royalties. As of December 31, 2013, the aggregate, undiscounted amount of contingent consideration that we could pay related to the acquisitions ranged from zero to $14.3 million (see “Note 5. Fair Value Measurements” below).
	On July 18, 2012, we entered into an asset purchase agreement with a global medical device company, pursuant to which we acquired substantially all of its assets for $6.0 million. In addition to the initial purchase price, we may be obligated to make revenue sharing payments based upon a percentage of net sales of products we acquired from it. We accounted for this acquisition under the purchase method of accounting and as a result, recorded goodwill of $5.6 million. The table below represents the assets acquired and liabilities assumed as part of this 2012 purchase:
	(In thousands)
	Inventory	$	158
	Identifiable intangible assets:
	Customer relationships	120
	Non-compete agreements	80
	Patents	2,420
	Contingent consideration	(2,311		)
	Total identifiable net assets	467
	Goodwill	5,564
	Net assets acquired	$	6,031
	These acquisitions, which expand our product pipeline, did not have a material effect on our consolidated net sales or operating income for the years ended December 31, 2014, 2013 or 2012. The assets acquired and liabilities assumed as a result of the acquisitions were included in our consolidated balance sheet as of the acquisition dates. The purchase price for each of the acquisitions was primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition dates. The fair value assigned to identifiable intangible assets acquired was determined primarily by using the income approach, which discounts expected future cash flows to present value using estimates and assumptions determined by management. Purchased identifiable intangible assets are amortized on a straight-line basis over their respective estimated useful lives. The excess purchase price over the value of the net tangible and identifiable intangible assets was recorded as goodwill. The goodwill from these acquisitions is deductible for tax purposes.
	The fair value of the IPR&D was determined using a relief from royalty approach, including a pre-tax royalty rate ranging between 4% and 9% and a discount rate ranging between 13.5% and 19%. IPR&D will become an amortizable asset upon completion of the projects, which are currently expected to be completed between 2016 and 2020. The estimated costs to complete the IPR&D projects are approximately $14.1 million as of December 31, 2014.
	The following table provides a reconciliation of the beginning and ending balances of contingent payments associated with acquisitions during the years ended December 31, 2014 and December 31, 2013:
	(In thousands)
	Balance at December 31, 2012	$	7,358
	Purchase price contingent consideration	6,704
	Contingent payments	(5		)
	Changes in fair value of contingent consideration classified in operating expenses	120
	Balance at December 31, 2013	14,177
	Purchase price contingent consideration	11,300
	Contingent payments	(11		)
	Changes in fair value of contingent consideration classified in operating expenses (1)	(1,131		)
	Balance at December 31, 2014	$	24,335
	(1)	Reduction in fair value during 2014 due primarily to reductions to a contingent royalty accrual, offset partially by increases in other royalty and milestone accruals.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2014
Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure	INTANGIBLE ASSETS
	A summary of intangible assets is presented below:
				December 31, 2014
	(In thousands)	Weighted-		Gross			Accumulated Amortization				Intangible
		Average Amortization		Carrying							Assets, net
		Period		Amount
		(in years)
	In-process research & development	—		$	24,560		$	—			$	24,560
	Supplier network	10		3,800			(88		)		3,712
	Customer relationships & other intangibles	7.3		5,525			(1,344		)		4,181
	Patents	17		2,420			(344		)		2,076
	Total intangible assets			$	36,305		$	(1,776	)		$	34,529
				December 31, 2013
	(In thousands)	Weighted-		Gross			Accumulated Amortization				Intangible
		Average Amortization		Carrying							Assets, net
		Period		Amount
		(in years)
	In-process research & development	—		$	24,560		$	—			$	24,560
	Customer relationships & other intangibles	9.5		3,623			(864		)		2,759
	Patents	17		2,420			(202		)		2,218
	Total intangible assets			$	30,603		$	(1,066	)		$	29,537
	Amortization expense was as follows:
	(in thousands)		31-Dec-14			December 31, 2013				December 31, 2012
	Intangible asset amortization expense		$	710		$	528			$	468
	Expected future intangible asset amortization as of December 31, 2014 is as follows:
	(In thousands)		Annual Amortization
	Year ending December 31:
	2015		$	1,545
	2016		1,541
	2017		1,423
	2018		856
	2019		852
	Thereafter		3,752
	Total		$	9,969

MARKETABLE_SECURITIES

MARKETABLE SECURITIES	12 Months Ended
	Dec. 31, 2014
Marketable Securities [Abstract]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure	MARKETABLE SECURITIES
	The composition of our short-term and long-term marketable securities is as follows:
			31-Dec-14
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	28,684	$	2	$	(3	)	$	28,683
	Corporate debt securities	Less than 1	73,066		7		(42		)	73,031
	Commercial paper	Less than 1	44,663		8		—			44,671
	Asset backed securities	Less than 1	54		—		—			54
	Total short-term marketable securities		$	146,467	$	17	$	(45	)	$	146,439
	Long-term:
	Municipal bonds	2-Jan	$	26,005	$	3	$	(36	)	$	25,972
	Corporate debt securities	2-Jan	19,617		3		(22		)	19,598
	Asset backed securities	2-Jan	21,236		1		(8		)	21,229
	Securities of U.S. government-sponsored agencies	2-Jan	8,564		—		(16		)	8,548
	Total long-term marketable securities		$	75,422	$	7	$	(82	)	$	75,347
			31-Dec-13
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	77,342	$	17	$	(15	)	$	77,344
	Corporate debt securities	Less than 1	35,525		15		(11		)	35,529
	Commercial paper	Less than 1	36,083		6		—			36,089
	Total short-term marketable securities		$	148,950	$	38	$	(26	)	$	148,962
	Long-term:
	Municipal bonds	2-Jan	$	12,304	$	13	$	(1	)	$	12,316
	Corporate debt securities	2-Jan	17,533		27		—			17,560
	Asset backed securities	2-Jan	6,651		2		(1		)	6,652
	Total long-term marketable securities		$	36,488	$	42	$	(2	)	$	36,528

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS
	Under the accounting for fair value measurements and disclosures, fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or the liability in an orderly transaction between market participants on the measurement date. Additionally, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable inputs. The level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	Our assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:
	Level 1—quoted prices (unadjusted) in active markets for identical assets and liabilities;
	Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; and
	Level 3—unobservable inputs in which there is little or no market data available, which require the reporting entity to use significant unobservable inputs or valuation techniques.
	The fair value of our assets and liabilities measured at fair value on a recurring basis was as follows:
		Balance at
	(In thousands)	December 31,		Level 1		Level 2		Level 3
		2014
	Assets
	Cash equivalents	$	9,802	$	1,302	$	8,500	$	—
	Municipal bonds	54,655		—		54,655		—
	Corporate debt securities	92,629		—		92,629		—
	Commercial paper	44,671		—		44,671		—
	Asset-backed securities	21,283		—		21,283		—
	Securities of U.S. government-sponsored agencies	8,548		—		8,548		—
	Liabilities
	Contingent consideration	24,335		—		—		24,335
		Balance at
	(In thousands)	December 31,		Level 1		Level 2		Level 3
		2013
	Assets
	Cash equivalents	$	20,363	$	800	$	19,563	$	—
	Municipal bonds	89,660		—		89,660		—
	Corporate debt securities	53,089		—		53,089		—
	Commercial paper	36,089		—		36,089		—
	Asset-backed securities	6,652		—		6,652		—
	Liabilities
	Contingent consideration	14,177		—		—		14,177
	Contingent consideration represents our contingent milestone, performance and revenue-sharing payment obligations related to our acquisitions and is measured at fair value and is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions we believe would be made by a market participant, such as the probabilities associated with successfully completing clinical trials and obtaining regulatory approval, of achieving sales milestones and the period in which these milestones are expected to be achieved, as well as discount rates, which range from 3.1% to 13.5%. We assess these estimates on an ongoing basis as additional data impacting the assumptions is obtained. Changes in the fair value of contingent consideration related to updated assumptions and estimates are recognized within research and development and selling, general and administrative expenses in the consolidated statements of income.
	Assets and Liabilities That Are Measured at Fair Value on a Nonrecurring Basis
	The purchase price of business acquisitions is primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition dates, with the excess recorded as goodwill. We utilize Level 3 inputs in the determination of the initial fair value. Non-financial assets such as goodwill, intangible assets, and property, plant, and equipment are subsequently measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment is recognized. We assess the impairment of intangible assets annually or whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. The fair value of our goodwill and intangible assets is not estimated if there is no change in events or circumstances that indicate the carrying amount of an intangible asset may not be recoverable. We have not recorded impairment charges related to our business acquisitions.

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	INVENTORIES
	(In thousands)	December 31, 2014		December 31, 2013
	Raw materials	$	8,847	$	1,369
	Work in process	2,490		2,820
	Finished goods	79,608		66,161
	Total	$	90,945	$	70,350

PROPERTY_EQUIPMENT

PROPERTY & EQUIPMENT	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property And Equipment	PROPERTY AND EQUIPMENT
	(In thousands)	Useful Life		December 31, 2014				December 31, 2013
	Land	—		$	4,116			$	3,769
	Buildings and improvements	30		10,369				9,541
	Equipment	7-May		17,783				14,588
	Instruments	3		123,864				107,867
	Modules and cases	3		25,155				22,325
	Other property and equipment	5-Mar		6,732				5,970
				188,019				164,060
	Less: accumulated depreciation			(118,544		)		(99,910		)
	Total			$	69,475			$	64,150
	Instruments are hand-held devices used by surgeons to install implants during surgery. Modules and cases are used to store and transport the instruments and implants.
	Depreciation expense related to property and equipment was as follows:
	(In thousands)	31-Dec-14				December 31, 2013				December 31, 2012
	Depreciation	$	21,044			$	18,869			$	17,640

ACCRUED_EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]
Accrued Expenses	ACCRUED EXPENSES
	(In thousands)	December 31,		December 31,
		2014		2013
	Compensation and other employee-related costs	$	19,933	$	17,428
	Legal and other settlements and expenses	27,686		23,765
	Accrued non-income taxes	4,720		2,938
	Other	9,160		6,994
	Total accrued expenses	$	61,499	$	51,125

DEBT

DEBT	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt	DEBT
	Line of Credit
	In May 2011, we entered into a credit agreement with Wells Fargo Bank related to a revolving credit facility that provides for borrowings up to $50.0 million. At our request, and with the approval of the bank, the amount of borrowings available under the revolving credit facility can be increased to $75.0 million. The revolving credit facility includes up to a $25.0 million sub-limit for letters of credit. As amended to date, the revolving credit facility extends to May 2015. Cash advances bear interest at our option either at a fluctuating rate per annum equal to the daily LIBOR in effect for a one-month period plus 0.75%, or a fixed rate for a one- or three-month period equal to LIBOR plus 0.75%. The credit agreement governing the revolving credit facility also subjects us to various restrictive covenants, including the requirement to maintain maximum consolidated leverage. The covenants also include limitations on our ability to repurchase shares, to pay cash dividends or to enter into a sale transaction. As of December 31, 2014, we were in compliance with all covenants under the credit agreement, there were no outstanding borrowings under the revolving credit facility and available borrowings were $50.0 million. We may terminate the credit agreement at any time on ten days’ notice without premium or penalty.

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Equity	EQUITY
	Our amended and restated Certificate of Incorporation provides for a total of 785,000,000 authorized shares of common stock. Of the authorized number of shares of common stock, 500,000,000 shares are designated as Class A common stock (“Class A Common”), 275,000,000 shares are designated as Class B common stock (“Class B Common”) and 10,000,000 shares are designated as Class C common stock (“Class C Common”).
	The holders of Class A Common are entitled to one vote for each share of Class A Common held. The holders of Class B Common are entitled to 10 votes for each share of Class B Common held. The holders of Class A Common and Class B Common vote together as one class of common stock. The Class C Common is nonvoting. Except for voting rights, the Class A Common, Class B Common and Class C Common have the same rights and privileges.
	In August 2012, we completed our IPO. We sold 2,083,333 shares of our Class A Common at an offering price of $12.00 per share. We recognized gross proceeds of $25.0 million and our net proceeds received after underwriting fees and offering expenses were $21.0 million.
	Immediately prior to the closing of our IPO, we effectuated the following conversion:
	•	the automatic conversion of all shares of our Series E preferred stock to 15,597,300 shares of our Class B Common;
	•	the subsequent automatic conversion of 49,655,411 shares of our Class B Common (which reflects all such shares of Class B Common held by those who beneficially owned less than 10% of the aggregate number of all outstanding shares of our common stock) to 49,655,411 shares of our Class A Common;
	•	the automatic conversion of all shares of our Class C Common to 73,554 shares of our Class A Common; and
	•	the automatic conversion of 3,039,385 shares of Class B Common to 3,039,385 shares of Class A Common upon their sale by the selling stockholders.
	Our issued and outstanding common shares by Class were as follows:
	(Shares)	Class A Common	Class B	Total
			Common
	December 31, 2014	70,828,187	23,877,556	94,705,743
	31-Dec-13	66,065,197	27,377,556	93,442,753

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	STOCK-BASED COMPENSATION
	We have three stock plans: our Amended and Restated 2003 Stock Plan, our 2008 Stock Plan, and our 2012 Equity Incentive Plan (the "2012 Plan"). The 2012 Plan is the only remaining active stock plan.  The purpose of these stock plans was, and the 2012 Plan is, to provide incentive to employees, directors, and consultants of Globus.  The Plans are administered by the Board or its delegates. The number, type of option, exercise price, and vesting terms are determined by the Board or its delegates in accordance with the terms of the Plans. The options granted expire on a date specified by the Board, but generally not more than ten years from the grant date. Option grants to employees generally vest monthly over a four-year period.
	The 2012 Plan was approved by our Board in March 2012, and by our stockholders in June 2012. Under the 2012 Plan, the aggregate number of shares of Class A Common that may be issued subject to options and other awards is equal to the sum of (i) 3,076,923 shares, (ii) any shares available for issuance under the 2008 Plan as of March 13, 2012, (iii) any shares underlying awards outstanding under the 2008 Plan as of March 13, 2012 that, on or after that date, are forfeited, terminated, expired or lapse for any reason, or are settled for cash without delivery of shares and (iv) starting January 1, 2013, an annual increase in the number of shares available under the 2012 Plan equal to up to 3% of the number of shares of our common and preferred stock outstanding at the end of the previous year, as determined by our Board. The number of shares that may be issued or transferred pursuant to incentive stock options under the 2012 Plan is limited to 10,769,230 shares. The shares of Class A Common covered by the 2012 Plan are authorized but unissued shares, treasury shares or shares of common stock purchased on the open market.
	As of December 31, 2014, pursuant to the 2012 Plan, there were 9,085,832 shares of Class A Common stock reserved and 6,019,966 shares of Class A Common stock available for future grants.
	The weighted average grant date per share fair values of the options awarded to employees were as follows:
			Year Ended
			December 31,				December 31,				December 31,
			2014				2013				2012
	Weighted average grant date per share fair value		$	9.63			$	6.34			$	5.9
	The fair value of the options was estimated on the date of the grant using a Black-Scholes option pricing model with the following assumptions:
		Year Ended
		December 31,						December 31,					December 31,
		2014						2013					2012
	Risk-free interest rate	1.51	%	-	1.95	%		0.98	%	-	1.74	%	0.9	%	-	1.1	%
	Expected term (years)	5.3		-	6.4			6.1		-	6.4		6
	Expected volatility	35	%	-	41	%		41	%	-	44	%	44	%	-	47	%
	Expected dividend yield	—%						—%					—%
	Stock option activity during the years ended December 31, 2014, 2013 and 2012 is summarized as follows:
		Option Shares (thousands)			Weighted average exercise price				Weighted average remaining contractual life (years)		Aggregate intrinsic value (thousands)
	Outstanding at December 31, 2011	6,454			$	5.14
	Granted	1,228			13.1
	Exercised	(1,061	)		1.42
	Forfeited	(368	)		9.55
	Outstanding at December 31, 2012	6,253			6.99
	Granted	1,222			14.78
	Exercised	(2,173	)		3.48
	Forfeited	(416	)		12.23
	Outstanding at December 31, 2013	4,886			10.04
	Granted	1,495			23.45
	Exercised	(1,263	)		7.71
	Forfeited	(264	)		15.33
	Outstanding at December 31, 2014	4,854			14.5				7.1		$	45,731
	Exercisable at December 31, 2014	2,390			9.08				5.4		35,093
	Expected to vest at December 31, 2014	2,464			$	19.76			8.8		$	10,638
	We use the Black Scholes pricing model to determine the fair value of our stock options (see “Note 1. Background and Summary of Significant Accounting Policies, (q) Stock-Based Compensation” above). Subsequent to the February 2012 and March 2012 stock option grants, we reassessed the fair value of our stock options on those dates of grant by updating the assumptions and facts considered in an October 2011 valuation report upon which we relied to take into account our actual results, market conditions, comparable company results, and the timing of our IPO.
	Compensation expense related to stock options granted to employees and non-employees under the Plans and the intrinsic value of stock options exercised was as follows:
			Year Ended
	(In thousands)		December 31,				December 31,				December 31,
			2014				2013				2012
	Compensation expense related to stock options		$	7,111			$	5,177			$	4,635
	Intrinsic value of stock options exercised		20,216				25,034				12,507
	As of December 31, 2014, there was $16.1 million of unrecognized compensation expense related to unvested employee stock options that vest over a weighted average period of three years.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES
	The components of income before income taxes are as follows:
						Year ended
	(In thousands)	31-Dec-14				December 31, 2013				December 31, 2012
	Domestic	$	137,643			$	101,424			$	114,176
	Foreign	999				577				477
	Total	$	138,642			$	102,001			$	114,653
	The components of the provision/(benefit) for income taxes are as follows:
						Year ended
	(In thousands)	31-Dec-14				December 31, 2013				December 31, 2012
	Current:
	Federal	$	43,561			$	41,741			$	40,338
	State	6,097				6,118				6,419
	Foreign	519				912				345
		50,177				48,771				47,102
	Deferred:
	Federal	(3,630		)		(14,088		)		(5,510		)
	State	(357		)		(1,210		)		(352		)
	Foreign	(33		)		(84		)		(418		)
		(4,020		)		(15,382		)		(6,280		)
	Total	$	46,157			$	33,389			$	40,822
	A reconciliation of the statutory U.S. federal tax rate to our effective rate is as follows:
		Year ended
		31-Dec-14			December 31, 2013			December 31, 2012
	Statutory U.S. federal tax rate	35	%		35	%		35	%
	State income taxes, net of federal benefit	2.6			2.8			2.9
	Domestic production activities deduction	(2.7	)		(3.5	)		(2.3	)
	Tax credits	(1.2	)		(1.7	)		(0.1	)
	Nondeductible expenses	0.7			1.7			1.4
	Other	(1.1	)		(1.6	)		(1.3	)
	Effective tax rate	33.3	%		32.7	%		35.6	%
	Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes. Significant components of our deferred income taxes are as follows:
	(In thousands)	31-Dec-14				December 31, 2013
	Deferred tax assets:
	Inventory reserve	$	22,808			$	19,635
	Accruals, reserves, and other currently not deductible	19,043				17,133
	Stock-based compensation	5,548				5,152
	Foreign net operating loss carryforwards	418				724
	Total deferred tax assets	47,817				42,644
	Valuation allowance	(45		)		(327		)
	Total deferred tax assets, net of valuation allowance	47,772				42,317
	Deferred tax liabilities:
	Depreciation and amortization	(9,865		)		(9,759		)
	Other	(2,643		)		(1,229		)
	Total deferred tax liabilities	(12,508		)		(10,988		)
	Net deferred tax assets	$	35,264			$	31,329
	In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based upon the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, management believes it is more likely than not that we will realize the benefits of these deductible differences at December 31, 2014. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced. Of the amounts presented above, $0.4 million of long-term deferred tax assets is included as a component of other assets on our consolidated balance sheet as of December 31, 2014 and 2013.
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
						Year ended
	(In thousands)	31-Dec-14				December 31, 2013				December 31, 2012
	Unrecognized tax benefits at the beginning of the year	$	3,978			$	3,500			$	2,799
	Additions related to current year tax positions	—				661				673
	Additions related to prior year tax positions	614				64				46
	Reductions related to prior year tax positions	(209		)		(109		)		(18		)
	Lapse of statute of limitations	(202		)		(138		)		—
	Settlements	(953		)		—				—
	Unrecognized tax benefits at the end of the year	$	3,228			$	3,978			$	3,500
	The impact of our unrecognized tax benefits to the effective income tax rate is as follows:
	(In thousands)	31-Dec-14				December 31, 2013				December 31, 2012
	Portion of total unrecognized tax benefits that, if recognized, would affect the effective income tax rate	$	838			$	1,184			$	747
	Interest and penalties are recorded in the statement of operations as provision for income taxes. The total interest and penalties recorded in the statement of operations was nominal for the years ended December 31, 2014, 2013 and 2012. Our uncertain tax benefits could increase in the next twelve months as we continue our current transfer pricing policies and deduct additional tax credits. We are unable to estimate a range of reasonably possible changes in our uncertain tax benefits in the next twelve months. In 2014, we settled the IRS audits of 2011 and 2012 tax years, resulting in no adjustments. The tax years that remained subject to examination by a major tax jurisdiction as of December 31, 2014 were 2009 and beyond for Switzerland; 2010 and beyond for India, Belgium, Germany, and Poland; 2011 and beyond for Denmark, Sweden and Australia; 2012 and beyond for South Africa and Israel; 2013 and beyond for the United States, the United Kingdom, Netherlands, and France.
	On December 19, 2014, the Tax Increase Prevention Act of 2014 (the “TIPA”) was signed into law. One of the provisions of the TIPA was the reinstatement of the research and experimentation tax credit from January 1, 2014 through December 31, 2014. As of December 31, 2014 a benefit was recognized for this tax credit and is included in the 2014 tax provision.
	On January 2, 2013, the American Taxpayer Relief Act of 2012 (the “ATRA”) was signed into law. One of the provisions of the ATRA was a reinstatement and extension of the research and experimentation tax credit from January 1, 2012 through December 31, 2013. However, as of December 31, 2012 no benefit could be recognized for this tax credit due to the passage of the ATRA in 2013. As the passage of the ATRA occurred in 2013, the entire reinstated credit for the year ended December 31, 2012 of $0.9 million was recognized in 2013 in accordance with accounting guidance.

LEASES

LEASES	12 Months Ended
	Dec. 31, 2014
Leases, Operating [Abstract]
Leases	LEASES
	The Company leases certain equipment and office facilities under operating leases. As of December 31, 2014, minimum future rental payments under operating leases for each of the next five years are as follows:
	(In thousands)
	Year ending December 31:
	2015	$	700
	2016	546
	2017	279
	2018	105
	2019	—
	Thereafter	—
	Total	$	1,630
	Rent expense related to all operating leases recognized as a component of selling, general and administrative expenses was as follows:
				Year ended
	(In thousands)	31-Dec-14		December 31, 2013		December 31, 2012
	Rent expense	$	676	$	424	$	419

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES
	We are involved in a number of proceedings, legal actions, and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within our control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, including injunctions prohibiting us from engaging in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. We record a liability in the consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. While it is not possible to predict the outcome for most of the matters discussed, we believe it is possible that costs associated with them could have a material adverse impact on our consolidated earnings, financial position or cash flows.
	N-Spine, Synthes and Depuy Synthes Litigation
	In April 2010, N-Spine, Inc. and Synthes USA Sales, LLC filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. N-Spine, the patent owner, and Synthes USA, a licensee of the subject patent, allege that we infringe one or more claims of the patent by making, using, offering for sale or selling our TRANSITION® stabilization system product. N-Spine and Synthes USA seek injunctive relief and an unspecified amount in damages. We intend to defend our rights vigorously. This matter was stayed on July 14, 2011 pending the resolution of an inter partes reexamination on the asserted patent granted by the U.S. Patent and Trademark Office (“USPTO”) in February 2011. In December 2011, the examiner withdrew the original grounds of rejection of the asserted patent and we appealed the examiner’s decision. In January 2014, the USPTO ruled on the appeal, rejecting certain claims in view of the prior art and affirming certain other claims. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	In a related matter, on January 8, 2014, Depuy Synthes Products, LLC (“Depuy Synthes”) filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. Depuy Synthes alleges that we infringe one or more claims of the asserted patent by making, using, offering for sale or selling our TRANSITION® stabilization system product. Depuy Synthes seeks injunctive relief and an unspecified amount in damages. We intend to defend our rights vigorously. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	Synthes USA, LLC, Synthes USA Products, LLC and Synthes USA Sales, LLC Litigation
	In July 2011, Synthes USA, LLC, Synthes USA Products, LLC and Synthes USA Sales, LLC filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. Synthes USA LLC, the patent owner, Synthes USA Products, LLC, a licensee to manufacture products of the subject patents, and Synthes USA Sales LLC, a licensee to sell products of the subject patents, allege that we infringe one or more claims of three patents by making, using, offering for sale or selling our COALITION®, INDEPENDENCE® and INTERCONTINENTAL® products. As a result of the acquisition of Synthes, Inc. by Johnson & Johnson, a motion was filed to change the plaintiff in this matter to DePuy Synthes in February 2013. On June 14, 2013, the jury in this case returned a verdict, finding that prior versions of the three products we previously sold did infringe on DePuy Synthes’ patents and awarding monetary damages in the amount of $16.0 million. The jury also upheld the validity of DePuy Synthes’ patents. There was no finding of willful infringement by Globus.
	We do not expect the verdict to impact our ability to conduct our business or to have any material impact on our future revenues. As this lawsuit involved only three products that are no longer part of our product portfolio, this verdict is not expected to impair our ability to sell any of our future products.
	We believe the facts and the law do not support the jury’s findings of infringement and patent validity and are seeking to overturn the verdict through the appeals process.
	For the year ended December 31, 2013, we accrued $19.5 million in damages and other litigation-related costs related to this case, of which $1.3 million was included in provision for litigation loss (cost of goods sold, due to a write off of certain inventory which will not be sold due to the verdict) and $18.2 million was included in provision for litigation loss (operating expense). During the year ended December 31, 2014, we accrued an additional $0.6 million in interest included in provision for litigation related to this litigation.
	L5 Litigation
	In December 2009, we filed suit in the Court of Common Pleas of Montgomery County, Pennsylvania against our former exclusive independent distributor L5 Surgical, LLC and its principals, seeking an injunction and declaratory judgment concerning certain restrictive covenants made to L5 by its sales representatives. L5 brought counterclaims against us alleging tortious interference, unfair competition and conspiracy. The injunction phase was resolved in September 2010, and this matter is now in the discovery phase of litigation on the underlying damages claims. We intend to defend our rights vigorously. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	NuVasive Litigation
	In October 2010, NuVasive, Inc. filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. NuVasive, the patent owner, alleges that we infringe one or more claims of three patents by making, using, offering for sale or selling our MARS™ 3V retractor for use in certain lateral fusion procedures. NuVasive sought injunctive relief and an unspecified amount in damages. This matter was settled on Feburary 12, 2015 for an undisclosed amount.
	NuVasive Employee Litigation
	We have hired several employees who were formerly employed by NuVasive, Inc. In July 2011, NuVasive filed suit against us in the District Court of Travis County, Texas alleging that our hiring of one named former employee and other unnamed former employees constitutes tortious interference with its contracts with those employees, and with prospective business relationships, as well as aiding and abetting the breach of fiduciary duty. NuVasive sought compensatory damages, permanent injunction, punitive damages and attorneys’ fees. This matter was settled on Feburary 12, 2015 for an undisclosed amount.
	Bianco Litigation
	On March 21, 2012, Sabatino Bianco filed suit against us in the Federal District Court for the Eastern District of Texas claiming that we misappropriated his trade secret and confidential information and improperly utilized it in developing our CALIBER® product. Bianco alleges that we engaged in misappropriation of trade secrets, breach of contract, unfair competition, fraud and theft and seeks correction of inventorship, injunctive relief and exemplary damages. On April 20, 2012, Bianco filed a motion for a preliminary injunction, seeking to enjoin us from making, using, selling, importing or offering for sale our CALIBER® product. On November 15, 2012, the court denied Bianco’s motion for preliminary injunction. On October 1, 2013, Bianco amended his complaint to include that his trade secrets and confidential information were also used improperly in developing our RISE® and CALIBER®-L products.
	On January 17, 2014, the jury in this case returned a verdict in favor of Bianco on a claim of misappropriation of trade secret. We have accrued the verdict amount of $4.3 million as of December 31, 2013. The jury found against Bianco on the claims of breach of contract and disgorgement of profits. The court granted our motion for judgment as a matter of law and dismissed Bianco’s claims for unfair competition, fraud, and exemplary damages, and Bianco abandoned the claim of misappropriation of confidential information. Bianco’s claims of correction of inventorship, unjust enrichment, and permanent injunctive relief were not submitted to the jury. On March 7, 2014, the court denied Bianco’s claim for correction of inventorship and ruled he is not entitled to be named as a co-inventor on any of the patents at issue, and also denied his claim for unjust enrichment. On March 17, 2014, the court denied Bianco’s claim for permanent injunctive relief. On July 2, 2014, the court awarded Bianco an ongoing royalty of 5% of the net sales of the CALIBER®, CALIBER®-L, and RISE® products, or products that are not colorably different from those products, for a fifteen year period on sales starting on January 18, 2014. The court entered final judgment on the jury verdict on July 17, 2014. Post-trial motions were denied on October 27, 2014 and the matter is currently on appeal.
	We do not expect the verdict to impact our ability to conduct our business or to have any material impact on our future revenues. We believe the facts and the law do not support the jury’s findings of misappropriation of trade secret and are seeking to overturn the verdict through the appeals process.
	Altus Partners, LLC Litigation
	On February 20, 2013, Altus Partners, LLC filed suit against us in the U.S. District Court for the Eastern District of Pennsylvania for patent infringement.  On April 7, 2014, we settled the litigation with Altus Partners and recognized a provision for litigation of $2.0 million.
	Bonutti Skeletal Innovations, LLC Litigation
	On November 19, 2014, Bonutti Skeletal Innovations, LLC filed suit against us in the U.S. District Court for the Eastern District of Pennsylvania for patent infringement. Bonutti Skeletal, a non-practicing entity, alleges that Globus willfully infringes one or more claims of six patents by making, using, offering for sale or selling the CALIBER®, CALIBER®-L, COALITION®, CONTINENTAL®, FORGE®, FORTIFY®, INDEPENDENCE®, INTERCONTINENTAL®, MONUMENT®, NIKO®, RISE®, SIGNATURE®, SUSTAIN®, and TRANSCONTINENTAL® products. Bonutti Skeletal seeks an unspecified amount in damages and injunctive relief. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	In addition, we are subject to legal proceedings arising in the ordinary course of business.

RETIREMENT_BENEFIT_PLANS

RETIREMENT BENEFIT PLANS	12 Months Ended
	Dec. 31, 2014
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]
Retirement Benefit Plans	RETIREMENT BENEFIT PLANS
	We sponsor a 401(k) Plan covering all eligible U.S. employees. Under the 401(k) Plan, we make nondiscretionary matching contributions at the rate of 100% of employee’s contributions up to a maximum annual contribution of $6,000 per eligible employee, limited to 3% of the employee’s compensation for the period.
	Additionally, we contribute to various foreign retirement benefit plans required by local law or coordinated with government sponsored plans which cover many of our international employees. The benefits offered under these plans are reflective of local customs and practices in the countries concerned.
	Company contributions to these retirement plans were as follows:
		Year ended
	(In thousands)	31-Dec-14		December 31, 2013		December 31, 2012
	401(k) and other retirement plan contributions	$	2,185	$	2,106	$	1,055

RELATEDPARTY_TRANSACTIONS

RELATED-PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related-Party Transactions	RELATED-PARTY TRANSACTIONS
	We have contracted with a third-party manufacturer in which certain of our senior management and significant stockholders have or had ownership interests and leadership positions.
	We have purchased the following amounts of products and services from the supplier:
		Year Ended
	(In thousands)	December 31, 2014		December 31,		December 31,
				2013		2012
	Purchases from related-party supplier	$	21,948	$	20,039	$	20,159
	As of December 31, 2014 and December 31, 2013, we had $5.4 million and $2.7 million of accounts payable due to the supplier.

SEGMENT_AND_GEOGRAPHIC_INFORMA

SEGMENT AND GEOGRAPHIC INFORMATION	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment And Geographic Information	SEGMENT AND GEOGRAPHIC INFORMATION
	Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We globally manage the business within one reportable segment. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. Products are sold principally in the United States.
	The following table represents total sales by geographic area, based on the location of the customer:
		Year Ended
	(In thousands)	December 31,		December 31,		December 31,
		2014		2013		2012
	United States	$	427,091	$	396,615	$	355,609
	International	47,280		37,844		30,385
	Total sales	$	474,371	$	434,459	$	385,994
	We classify our products into two categories: Innovative Fusion products and Disruptive Technology products. The following table represents total sales by product category:
		Year Ended
	(In thousands)	December 31,		December 31,		December 31,
		2014		2013		2012
	Innovative Fusion	$	270,852	$	254,033	$	238,723
	Disruptive Technology	203,519		180,426		147,271
	Total sales	$	474,371	$	434,459	$	385,994

QUARTERLY_FINANCIAL_DATA_unaud

QUARTERLY FINANCIAL DATA (unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (unaudited)	QUARTERLY FINANCIAL DATA (unaudited)
		(unaudited)
	(In thousands, except per share amounts)	March 31,		June 30,		September 30,		December 31,
		2014		2014		2014		2014
	Sales	$	114,210	$	113,573	$	117,787	$	128,801
	Gross profit	88,898		86,990		90,101		97,525
	Net income	21,139		20,647		23,061		27,638
	Net earnings per common share - basic	0.23		0.22		0.24		0.29
	Net earnings per common share - diluted	0.22		0.22		0.24		0.29
		(unaudited)
	(In thousands, except per share amounts)	March 31,		June 30,		September 30,		December 31,
		2013		2013		2013		2013
	Sales	$	105,018	$	107,009	$	107,187	$	115,245
	Gross profit	81,525		82,248		81,872		88,471
	Net income	19,891		7,426		20,310		20,985
	Net earnings per common share - basic	0.22		0.08		0.22		0.22
	Net earnings per common share - diluted	0.21		0.08		0.22		0.22

SUBSEQUENT_EVENT

SUBSEQUENT EVENT	12 Months Ended
	Dec. 31, 2014
Subsequent Event
Subsequent Event	SUBSEQUENT EVENT
	On February 25, 2015, we entered into an agreement to acquire medical device manufacturer Branch Medical Group, Inc. (“BMG”), a third party manufacturer of high precision medical devices located in Audubon, PA. Under the terms of the agreement, we expect to pay approximately $52.9 million in cash subject to certain closing adjustments for BMG.
	We expect the closing of the acquisition to occur in March 2015 following satisfaction of the applicable closing conditions.

VALUATION_ACCOUNTS_AND_QUALIFY

VALUATION ACCOUNTS AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Valuation Accounts and Qualifying Accounts	VALUATION ACCOUNTS AND QUALIFYING ACCOUNTS
	Allowance for doubtful accounts:
	(In thousands)	Beginning of period		Additions		Write-offs			End of period
	Year ended December 31, 2012	$	602	$	363	$	(4	)	$	961
	Year ended December 31, 2013	961		693		(73		)	1,581
	Year ended December 31, 2014	$	1,581	$	318	$	(252	)	$	1,647
	Deferred tax valuation allowance:
	(In thousands)	Beginning of period		Additions		Write-offs			End of period
	Year ended December 31, 2012	$	1,149	$	—	$	(616	)	$	533
	Year ended December 31, 2013	533		—		(206		)	327
	Year ended December 31, 2014	$	327	$	—	$	(282	)	$	45

BACKGROUND_AND_SUMMARY_OF_SIGN1

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Principles of Consolidation	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Globus and its wholly owned subsidiaries. Our consolidation policy requires the consolidation of entities where a controlling financial interest is held. All intercompany balances and transactions are eliminated in consolidation.
Use of Estimates	Use of Estimates
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.
	Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, provision for excess and obsolete inventory, useful lives of assets, the outcome of litigation, and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.
Foreign Currency Translation	Foreign Currency Translation
	The functional currency of our foreign subsidiaries is their local currency. Assets and liabilities of the foreign subsidiaries are translated at the period end currency exchange rate and revenues and expenses are translated at an average currency exchange rate for the period. The resulting foreign currency translation gains and losses are included as a component of accumulated other comprehensive income. Gains and losses arising from intercompany foreign transactions are included in other income/(expense) on the consolidated statement of operations.
Cash and Cash Equivalents	Cash and Cash Equivalents
	Cash and cash equivalents include cash on hand and all highly liquid investments with a maturity of three months or less when purchased.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts
	The majority of our accounts receivable is composed of amounts due from hospitals. We carry our accounts receivable at cost less an allowance for doubtful accounts. On a regular basis, we evaluate our accounts receivable and estimate an allowance for doubtful accounts, as needed, based on various factors such as our customers’ current credit conditions, length of time past due, and the general economy as a whole. Receivables are written off against the allowance when they are deemed uncollectible.
Concentrations of Credit Risk	Concentrations of Credit Risk
	Financial instruments, which potentially subject us to concentrations of credit risk, are primarily cash and cash equivalents and accounts receivable. Concentrations of credit risk with respect to accounts receivable are limited due to the large number of entities comprising our customer base. We perform ongoing credit evaluations of our customers and generally do not require collateral.
	There was no customer that accounted for 10% or more of sales for the years ended December 31, 2014, 2013, and 2012, respectively.
Marketable Securities	Marketable Securities
	Our marketable securities include municipal bonds, corporate debt securities, commercial paper, securities of U.S. government-sponsored agencies and asset-backed securities, and are classified as available-for-sale as of December 31, 2014. Available-for-sale securities are recorded at fair value in both short-term and long-term marketable securities on our consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of accumulated other comprehensive income on our consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of our marketable securities are determined on a specific identification basis. Realized gains and losses, along with interest income and the amortization/accretion of premiums/discounts are included as a component of other income, net, on our consolidated statements of income. Interest receivable is recorded as a component of prepaid expenses and other current assets on our consolidated balance sheets.
	We maintain a portfolio of various holdings, types and maturities, though most of the securities in our portfolio could be liquidated at minimal cost at any time. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is considered to be other-than-temporary, the loss will be recognized in our consolidated statement of income in the period the determination is made.
Inventories	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The majority of our inventories are finished goods as we mainly utilize third-party suppliers to source our products. We periodically evaluate the carrying value of our inventories in relation to our estimated forecast of product demand, which takes into consideration the estimated life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a reserve for such excess inventories.
Property and Equipment	Property and Equipment
	Property and equipment are recorded at cost less accumulated depreciation. Additions or improvements are capitalized, while repairs and maintenance are expensed as incurred. Depreciation and amortization are provided using the straight-line method over the related useful lives of the assets.
	When assets are sold or otherwise disposed of, the related property, equipment, and accumulated depreciation amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.
Goodwill and Intangible Assets	Goodwill and Intangible Assets
	Goodwill represents the excess purchase price over the fair values of the identifiable assets acquired less the liabilities assumed. Goodwill is tested for impairment at a minimum on an annual basis. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount, to the fair value of the reporting unit. The fair values are estimated using an income and discounted cash flow approach. For the year ended December 31, 2014, we performed a qualitative test for impairment as permitted under Financial Accounting Standards Board (“FASB”) authoritative guidance. During the years ended December 31, 2014, 2013 and 2012, we did not record any impairment charges related to goodwill.
	Intangible assets consist of purchased in-process research and development (“IPR&D”), supplier network, patents, customer relationships and non-compete agreements. Intangible assets with finite useful lives are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from one to seventeen years. Intangible assets are tested for impairment annually or whenever events or circumstances indicate that a carrying amount of an asset (asset group) may not be recoverable. If impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset. Fair value is generally determined using a discounted future cash flow analysis.
	IPR&D has an indefinite life and is not amortized until completion of the project at which time the IPR&D becomes an amortizable asset. If the related project is not completed in a timely manner, we may have an impairment related to the IPR&D, calculated as the excess of the asset’s carrying value over its fair value.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	We periodically evaluate the recoverability of the carrying amount of long-lived assets, which include property and equipment, as well as whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be fully recoverable. An impairment is assessed when the undiscounted future cash flows from the use and eventual disposition of an asset group are less than its carrying value. If impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset group. Our fair value methodology is based on quoted market prices, if available. If quoted market prices are not available, an estimate of fair value is made based on prices of similar assets or other valuation techniques including present value techniques.
Revenue Recognition	Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, product delivery has occurred, pricing is fixed or determinable, and collection is reasonably assured. A significant portion of our revenue is generated from consigned inventory maintained at hospitals or with sales representatives. For these products, revenue is recognized at the time the product is used or implanted. For all other transactions, we recognize revenue when title to the goods and risk of loss transfer to customers, provided there are no remaining performance obligations that will affect the customer’s final acceptance of the sale. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold.
Research and Development	Research and Development
	Research and development costs are expensed as incurred. Research and development costs include salaries, employee benefits, supplies, consulting services, clinical services and clinical trial costs, and facilities costs. Costs incurred in obtaining technology licenses and patents are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use.
Stock-Based Compensation	Stock-Based Compensation
	The cost for employee and non-employee director awards is measured at the grant date based on the fair value of the award. The fair value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service period (generally the vesting period of the equity award). Awards issued to non-employees are recorded at their fair value as determined in accordance with authoritative guidance, and are periodically revalued as the awards vest and are recognized as expense over the requisite service period.
	The determination of the fair value of stock options is made utilizing the Black-Scholes option-pricing model which is affected by our stock price and a number of assumptions, including expected volatility, expected term, risk-free interest rate and expected dividends. The expected volatility is based upon the historical volatility of a public company peer group over the most recent period commensurate with the estimated expected term of the stock options. The expected term of the stock options is determined utilizing the simplified method given the limited extent of our historical data. The risk-free interest rate assumption is based on observed interest rates of U.S. Treasury securities appropriate for the expected terms of the stock options. The dividend yield assumption is based on the history and expectation of no dividend payouts.
Income Taxes	Income Taxes
	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which such items are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is established to offset any deferred tax assets if, based upon available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	Significant judgment is required in determining income tax provisions and in evaluating tax positions. We will establish additional provisions for income taxes when, despite the belief that tax positions are fully supportable, there remain certain positions that do not meet the minimum probability threshold that a tax position is more likely than not to be sustained upon examination by the taxing authority. In the normal course of business, we and our subsidiaries are examined by various federal, state, and foreign tax authorities. We regularly assess the potential outcomes of these examinations and any future examinations for the current or prior years in determining the adequacy of the provision for income taxes. We periodically assess the likelihood and amount of potential adjustments and adjust the income tax provision, the current tax liability, and deferred taxes in the period in which the facts that give rise to a revision become known.
Derivatives
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	As of December 31, 2014, the carrying values of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature. We classify our financial assets and liabilities that are measured at fair value into one of the three categories based upon inputs used to determine fair value.
Advertising Expense	Advertising Expense
	We expense advertising costs as they are incurred.
Legal costs	Legal Costs
	We expense legal costs related to loss contingencies as incurred.
Medical Device Excise Tax	Medical Device Excise Tax
	Effective as of January 1, 2013, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively “PPACA”) imposed a medical device excise tax (“MDET”) of 2.3% on any entity that manufactures or imports certain medical devices offered for sale in the United States. We account for the MDET as a component of our cost of goods sold.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements
	In May 2014, the FASB and the International Accounting Standards Board released a standard on the recognition of revenue from contracts with customers that is designed to create greater comparability for financial statement users across industries and jurisdictions. Under the new standard, an entity will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the payment to which the entity expects to be entitled in exchange for those goods or services. The standard also will require enhanced disclosures and provide more comprehensive guidance for transactions such as service revenue and contract modifications. The standard will take effect for public companies for annual reporting periods beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. We are currently evaluating the impact of the new standard on our financial position, results of operations and disclosures.

ACQUISTIONS_Tables

ACQUISTIONS (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Schedule of Assets Acquired and Liabilities Assumed	As of December 31, 2014, we recorded the following preliminary purchase price allocation for the identifiable tangible and intangible assets and liabilities of TTOT:
	(In thousands)
	Consideration:
	Cash paid at closing	$	36,128
	Contingent consideration	11,300			(1)
	Fair value of consideration	$	47,428
	Identifiable assets acquired and liabilities assumed:
	Inventory	$	9,599
	Supplier network	3,800
	Customer relationships	1,600
	Accounts receivable	1,529
	Equipment	518
	Trade names	300
	Other assets	292
	Accounts payable and accrued expenses	(5,034		)
	Total identifiable net assets	12,604
	Goodwill	34,824
	Total allocated purchase price	$	47,428
	-1	The contingent consideration relates to the achievement of certain sales milestones. As of December 31, 2014, the aggregate, undiscounted amount of contingent consideration that we could pay related to the acquisitions ranges from zero to $15.0 million (see “Note 5. Fair Value Measurements” below).
	On December 23, 2013, we entered into an asset purchase agreement with a small robotics development company, pursuant to which we acquired substantially all of its assets for $16.8 million. In addition to the initial purchase price, we may be obligated to make a milestone payment and revenue sharing payments based upon a percentage of net sales of certain products based on the intellectual property we acquired in the transaction. The acquired company was privately held and is focused on developing a next generation surgical robotic positioning platform for spine, brain and therapeutic markets. The technology is intended to enable surgeons to perform minimally invasive and percutaneous surgical procedures with greater accuracy, safety and reproducibility than is currently available. We accounted for this acquisition under the purchase method of accounting, and as a result, recorded goodwill of $3.0 million. The table below represents the valuation of the assets acquired and liabilities assumed as part of this 2013 purchase:
	(In thousands)
	Identifiable intangible assets:
	In-process research & development	$	20,460
	Non-compete agreements	20
	Contingent consideration	(6,704		)	(2)
	Total identifiable net assets	13,776
	Goodwill	2,999
	Net assets acquired	$	16,775
	-2	The contingent consideration relates to the achievement of certain regulatory milestones and royalties. As of December 31, 2013, the aggregate, undiscounted amount of contingent consideration that we could pay related to the acquisitions ranged from zero to $14.3 million (see “Note 5. Fair Value Measurements” below).
	On July 18, 2012, we entered into an asset purchase agreement with a global medical device company, pursuant to which we acquired substantially all of its assets for $6.0 million. In addition to the initial purchase price, we may be obligated to make revenue sharing payments based upon a percentage of net sales of products we acquired from it. We accounted for this acquisition under the purchase method of accounting and as a result, recorded goodwill of $5.6 million. The table below represents the assets acquired and liabilities assumed as part of this 2012 purchase:
	(In thousands)
	Inventory	$	158
	Identifiable intangible assets:
	Customer relationships	120
	Non-compete agreements	80
	Patents	2,420
	Contingent consideration	(2,311		)
	Total identifiable net assets	467
	Goodwill	5,564
	Net assets acquired	$	6,031
Contingent Consideration Rollforward Activity	The following table provides a reconciliation of the beginning and ending balances of contingent payments associated with acquisitions during the years ended December 31, 2014 and December 31, 2013:
	(In thousands)
	Balance at December 31, 2012	$	7,358
	Purchase price contingent consideration	6,704
	Contingent payments	(5		)
	Changes in fair value of contingent consideration classified in operating expenses	120
	Balance at December 31, 2013	14,177
	Purchase price contingent consideration	11,300
	Contingent payments	(11		)
	Changes in fair value of contingent consideration classified in operating expenses (1)	(1,131		)
	Balance at December 31, 2014	$	24,335
	(1)	Reduction in fair value during 2014 due primarily to reductions to a contingent royalty accrual, offset partially by increases in other royalty and milestone accruals.

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2014
Intangible Assets Disclosure [Abstract]
Intangible Assets Acquired as Part of Business Combination	A summary of intangible assets is presented below:
				December 31, 2014
	(In thousands)	Weighted-		Gross			Accumulated Amortization				Intangible
		Average Amortization		Carrying							Assets, net
		Period		Amount
		(in years)
	In-process research & development	—		$	24,560		$	—			$	24,560
	Supplier network	10		3,800			(88		)		3,712
	Customer relationships & other intangibles	7.3		5,525			(1,344		)		4,181
	Patents	17		2,420			(344		)		2,076
	Total intangible assets			$	36,305		$	(1,776	)		$	34,529
				December 31, 2013
	(In thousands)	Weighted-		Gross			Accumulated Amortization				Intangible
		Average Amortization		Carrying							Assets, net
		Period		Amount
		(in years)
	In-process research & development	—		$	24,560		$	—			$	24,560
	Customer relationships & other intangibles	9.5		3,623			(864		)		2,759
	Patents	17		2,420			(202		)		2,218
	Total intangible assets			$	30,603		$	(1,066	)		$	29,537
Schedule of intangible asset amortization expense	Amortization expense was as follows:
	(in thousands)		31-Dec-14			December 31, 2013				December 31, 2012
	Intangible asset amortization expense		$	710		$	528			$	468
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Expected future intangible asset amortization as of December 31, 2014 is as follows:
	(In thousands)		Annual Amortization
	Year ending December 31:
	2015		$	1,545
	2016		1,541
	2017		1,423
	2018		856
	2019		852
	Thereafter		3,752
	Total		$	9,969

MARKETABLE_SECURITIES_Tables

MARKETABLE SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2014
Marketable Securities [Abstract]
Marketable Securities	The composition of our short-term and long-term marketable securities is as follows:
			31-Dec-14
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	28,684	$	2	$	(3	)	$	28,683
	Corporate debt securities	Less than 1	73,066		7		(42		)	73,031
	Commercial paper	Less than 1	44,663		8		—			44,671
	Asset backed securities	Less than 1	54		—		—			54
	Total short-term marketable securities		$	146,467	$	17	$	(45	)	$	146,439
	Long-term:
	Municipal bonds	2-Jan	$	26,005	$	3	$	(36	)	$	25,972
	Corporate debt securities	2-Jan	19,617		3		(22		)	19,598
	Asset backed securities	2-Jan	21,236		1		(8		)	21,229
	Securities of U.S. government-sponsored agencies	2-Jan	8,564		—		(16		)	8,548
	Total long-term marketable securities		$	75,422	$	7	$	(82	)	$	75,347
			31-Dec-13
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	77,342	$	17	$	(15	)	$	77,344
	Corporate debt securities	Less than 1	35,525		15		(11		)	35,529
	Commercial paper	Less than 1	36,083		6		—			36,089
	Total short-term marketable securities		$	148,950	$	38	$	(26	)	$	148,962
	Long-term:
	Municipal bonds	2-Jan	$	12,304	$	13	$	(1	)	$	12,316
	Corporate debt securities	2-Jan	17,533		27		—			17,560
	Asset backed securities	2-Jan	6,651		2		(1		)	6,652
	Total long-term marketable securities		$	36,488	$	42	$	(2	)	$	36,528

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis	The fair value of our assets and liabilities measured at fair value on a recurring basis was as follows:
		Balance at
	(In thousands)	December 31,		Level 1		Level 2		Level 3
		2014
	Assets
	Cash equivalents	$	9,802	$	1,302	$	8,500	$	—
	Municipal bonds	54,655		—		54,655		—
	Corporate debt securities	92,629		—		92,629		—
	Commercial paper	44,671		—		44,671		—
	Asset-backed securities	21,283		—		21,283		—
	Securities of U.S. government-sponsored agencies	8,548		—		8,548		—
	Liabilities
	Contingent consideration	24,335		—		—		24,335
		Balance at
	(In thousands)	December 31,		Level 1		Level 2		Level 3
		2013
	Assets
	Cash equivalents	$	20,363	$	800	$	19,563	$	—
	Municipal bonds	89,660		—		89,660		—
	Corporate debt securities	53,089		—		53,089		—
	Commercial paper	36,089		—		36,089		—
	Asset-backed securities	6,652		—		6,652		—
	Liabilities
	Contingent consideration	14,177		—		—		14,177

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory
	(In thousands)	December 31, 2014		December 31, 2013
	Raw materials	$	8,847	$	1,369
	Work in process	2,490		2,820
	Finished goods	79,608		66,161
	Total	$	90,945	$	70,350

PROPERTY_EQUIPMENT_Tables

PROPERTY & EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property And Equipment
	(In thousands)	Useful Life		December 31, 2014				December 31, 2013
	Land	—		$	4,116			$	3,769
	Buildings and improvements	30		10,369				9,541
	Equipment	7-May		17,783				14,588
	Instruments	3		123,864				107,867
	Modules and cases	3		25,155				22,325
	Other property and equipment	5-Mar		6,732				5,970
				188,019				164,060
	Less: accumulated depreciation			(118,544		)		(99,910		)
	Total			$	69,475			$	64,150
Schedule Of Depreciation Of Property And Equipment	Depreciation expense related to property and equipment was as follows:
	(In thousands)	31-Dec-14				December 31, 2013				December 31, 2012
	Depreciation	$	21,044			$	18,869			$	17,640

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]
Accrued Expenses
	(In thousands)	December 31,		December 31,
		2014		2013
	Compensation and other employee-related costs	$	19,933	$	17,428
	Legal and other settlements and expenses	27,686		23,765
	Accrued non-income taxes	4,720		2,938
	Other	9,160		6,994
	Total accrued expenses	$	61,499	$	51,125

EQUITY_Tables

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Schedule of Issued and Outstanding Shares by Class	Our issued and outstanding common shares by Class were as follows:
	(Shares)	Class A Common	Class B	Total
			Common
	December 31, 2014	70,828,187	23,877,556	94,705,743
	31-Dec-13	66,065,197	27,377,556	93,442,753

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Grants in Period, Weighted Average Grant Date Fair Value	The weighted average grant date per share fair values of the options awarded to employees were as follows:
			Year Ended
			December 31,				December 31,				December 31,
			2014				2013				2012
	Weighted average grant date per share fair value		$	9.63			$	6.34			$	5.9
Fair Value of Options, Assumptions Schedule	The fair value of the options was estimated on the date of the grant using a Black-Scholes option pricing model with the following assumptions:
		Year Ended
		December 31,						December 31,					December 31,
		2014						2013					2012
	Risk-free interest rate	1.51	%	-	1.95	%		0.98	%	-	1.74	%	0.9	%	-	1.1	%
	Expected term (years)	5.3		-	6.4			6.1		-	6.4		6
	Expected volatility	35	%	-	41	%		41	%	-	44	%	44	%	-	47	%
	Expected dividend yield	—%						—%					—%
Summary of Stock Option Activity	Stock option activity during the years ended December 31, 2014, 2013 and 2012 is summarized as follows:
		Option Shares (thousands)			Weighted average exercise price				Weighted average remaining contractual life (years)		Aggregate intrinsic value (thousands)
	Outstanding at December 31, 2011	6,454			$	5.14
	Granted	1,228			13.1
	Exercised	(1,061	)		1.42
	Forfeited	(368	)		9.55
	Outstanding at December 31, 2012	6,253			6.99
	Granted	1,222			14.78
	Exercised	(2,173	)		3.48
	Forfeited	(416	)		12.23
	Outstanding at December 31, 2013	4,886			10.04
	Granted	1,495			23.45
	Exercised	(1,263	)		7.71
	Forfeited	(264	)		15.33
	Outstanding at December 31, 2014	4,854			14.5				7.1		$	45,731
	Exercisable at December 31, 2014	2,390			9.08				5.4		35,093
	Expected to vest at December 31, 2014	2,464			$	19.76			8.8		$	10,638
Stock Option Compensation Expense and Intrinsic Value Schedule	Compensation expense related to stock options granted to employees and non-employees under the Plans and the intrinsic value of stock options exercised was as follows:
			Year Ended
	(In thousands)		December 31,				December 31,				December 31,
			2014				2013				2012
	Compensation expense related to stock options		$	7,111			$	5,177			$	4,635
	Intrinsic value of stock options exercised		20,216				25,034				12,507

INCOME_TAXES_Income_Taxes_Tabl

INCOME TAXES Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income (loss) before Income Tax, Domestic and Foreign	The components of income before income taxes are as follows:
						Year ended
	(In thousands)	31-Dec-14				December 31, 2013				December 31, 2012
	Domestic	$	137,643			$	101,424			$	114,176
	Foreign	999				577				477
	Total	$	138,642			$	102,001			$	114,653
Schedule of Components Provision for Income Taxes	The components of the provision/(benefit) for income taxes are as follows:
						Year ended
	(In thousands)	31-Dec-14				December 31, 2013				December 31, 2012
	Current:
	Federal	$	43,561			$	41,741			$	40,338
	State	6,097				6,118				6,419
	Foreign	519				912				345
		50,177				48,771				47,102
	Deferred:
	Federal	(3,630		)		(14,088		)		(5,510		)
	State	(357		)		(1,210		)		(352		)
	Foreign	(33		)		(84		)		(418		)
		(4,020		)		(15,382		)		(6,280		)
	Total	$	46,157			$	33,389			$	40,822
U.S. Federal Tax Rate To Effective Rate Reconciliation	A reconciliation of the statutory U.S. federal tax rate to our effective rate is as follows:
		Year ended
		31-Dec-14			December 31, 2013			December 31, 2012
	Statutory U.S. federal tax rate	35	%		35	%		35	%
	State income taxes, net of federal benefit	2.6			2.8			2.9
	Domestic production activities deduction	(2.7	)		(3.5	)		(2.3	)
	Tax credits	(1.2	)		(1.7	)		(0.1	)
	Nondeductible expenses	0.7			1.7			1.4
	Other	(1.1	)		(1.6	)		(1.3	)
	Effective tax rate	33.3	%		32.7	%		35.6	%
Schedule of Components of Deferred Income Taxes	Significant components of our deferred income taxes are as follows:
	(In thousands)	31-Dec-14				December 31, 2013
	Deferred tax assets:
	Inventory reserve	$	22,808			$	19,635
	Accruals, reserves, and other currently not deductible	19,043				17,133
	Stock-based compensation	5,548				5,152
	Foreign net operating loss carryforwards	418				724
	Total deferred tax assets	47,817				42,644
	Valuation allowance	(45		)		(327		)
	Total deferred tax assets, net of valuation allowance	47,772				42,317
	Deferred tax liabilities:
	Depreciation and amortization	(9,865		)		(9,759		)
	Other	(2,643		)		(1,229		)
	Total deferred tax liabilities	(12,508		)		(10,988		)
	Net deferred tax assets	$	35,264			$	31,329
Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
						Year ended
	(In thousands)	31-Dec-14				December 31, 2013				December 31, 2012
	Unrecognized tax benefits at the beginning of the year	$	3,978			$	3,500			$	2,799
	Additions related to current year tax positions	—				661				673
	Additions related to prior year tax positions	614				64				46
	Reductions related to prior year tax positions	(209		)		(109		)		(18		)
	Lapse of statute of limitations	(202		)		(138		)		—
	Settlements	(953		)		—				—
	Unrecognized tax benefits at the end of the year	$	3,228			$	3,978			$	3,500
Impact of Unrecognized Tax Benefits to Effective Income Tax Rate	The impact of our unrecognized tax benefits to the effective income tax rate is as follows:
	(In thousands)	31-Dec-14				December 31, 2013				December 31, 2012
	Portion of total unrecognized tax benefits that, if recognized, would affect the effective income tax rate	$	838			$	1,184			$	747

LEASES_Tables

LEASES (Tables)	12 Months Ended
	Dec. 31, 2014
Leases, Operating [Abstract]
Schedule of Minimum Future Rental Payments Under Operating Leases	As of December 31, 2014, minimum future rental payments under operating leases for each of the next five years are as follows:
	(In thousands)
	Year ending December 31:
	2015	$	700
	2016	546
	2017	279
	2018	105
	2019	—
	Thereafter	—
	Total	$	1,630
Schedule of Rent Expense for Operating Leases	Rent expense related to all operating leases recognized as a component of selling, general and administrative expenses was as follows:
				Year ended
	(In thousands)	31-Dec-14		December 31, 2013		December 31, 2012
	Rent expense	$	676	$	424	$	419

RETIREMENT_BENEFIT_PLANS_Table

RETIREMENT BENEFIT PLANS (Tables)	12 Months Ended
	Dec. 31, 2014
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]
Company Contributions To Retirement Benefit Plans	Company contributions to these retirement plans were as follows:
		Year ended
	(In thousands)	31-Dec-14		December 31, 2013		December 31, 2012
	401(k) and other retirement plan contributions	$	2,185	$	2,106	$	1,055

RELATEDPARTY_TRANSACTIONS_Tabl

RELATED-PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	We have purchased the following amounts of products and services from the supplier:
		Year Ended
	(In thousands)	December 31, 2014		December 31,		December 31,
				2013		2012
	Purchases from related-party supplier	$	21,948	$	20,039	$	20,159

SEGMENT_AND_GEOGRAPHIC_INFORMA1

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Revenue from External Customers By Geographical Area International and Domestic	The following table represents total sales by geographic area, based on the location of the customer:
		Year Ended
	(In thousands)	December 31,		December 31,		December 31,
		2014		2013		2012
	United States	$	427,091	$	396,615	$	355,609
	International	47,280		37,844		30,385
	Total sales	$	474,371	$	434,459	$	385,994
Revenue from External Customers by Products and Services	The following table represents total sales by product category:
		Year Ended
	(In thousands)	December 31,		December 31,		December 31,
		2014		2013		2012
	Innovative Fusion	$	270,852	$	254,033	$	238,723
	Disruptive Technology	203,519		180,426		147,271
	Total sales	$	474,371	$	434,459	$	385,994

QUARTERLY_FINANCIAL_DATA_unaud1

QUARTERLY FINANCIAL DATA (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information
		(unaudited)
	(In thousands, except per share amounts)	March 31,		June 30,		September 30,		December 31,
		2014		2014		2014		2014
	Sales	$	114,210	$	113,573	$	117,787	$	128,801
	Gross profit	88,898		86,990		90,101		97,525
	Net income	21,139		20,647		23,061		27,638
	Net earnings per common share - basic	0.23		0.22		0.24		0.29
	Net earnings per common share - diluted	0.22		0.22		0.24		0.29
		(unaudited)
	(In thousands, except per share amounts)	March 31,		June 30,		September 30,		December 31,
		2013		2013		2013		2013
	Sales	$	105,018	$	107,009	$	107,187	$	115,245
	Gross profit	81,525		82,248		81,872		88,471
	Net income	19,891		7,426		20,310		20,985
	Net earnings per common share - basic	0.22		0.08		0.22		0.22
	Net earnings per common share - diluted	0.21		0.08		0.22		0.22

VALUATION_ACCOUNTS_AND_QUALIFY1

VALUATION ACCOUNTS AND QUALIFYING ACCOUNTS (Tables)	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts Disclosure
Summary of Valuation Allowance [Table Text Block]	Allowance for doubtful accounts:
	(In thousands)	Beginning of period		Additions		Write-offs			End of period
	Year ended December 31, 2012	$	602	$	363	$	(4	)	$	961
	Year ended December 31, 2013	961		693		(73		)	1,581
	Year ended December 31, 2014	$	1,581	$	318	$	(252	)	$	1,647
	Deferred tax valuation allowance:
	(In thousands)	Beginning of period		Additions		Write-offs			End of period
	Year ended December 31, 2012	$	1,149	$	—	$	(616	)	$	533
	Year ended December 31, 2013	533		—		(206		)	327
	Year ended December 31, 2014	$	327	$	—	$	(282	)	$	45

BACKGROUND_AND_SUMMARY_OF_SIGN2

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary of Significant Accounting Policies
Foreign currency transaction loss	($899,000)	($804,000)	($220,000)
Advertising expense	500,000	500,000	400,000
Restricted cash	23,370,000	0
Medical Device Excise Tax Percentage		2.30%
Minimum
Summary of Significant Accounting Policies
Number of Products Launched Since Inception	130
Estimated useful life of finite-lived intangible assets	1 year
Maximum
Summary of Significant Accounting Policies
Estimated useful life of finite-lived intangible assets	17 years
Cost of Goods, Total
Summary of Significant Accounting Policies
Medical Device Excise Tax	$7,100,000	$7,200,000

ACQUISTIONS_Textuals_Details

ACQUISTIONS (Textuals) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Oct. 23, 2014	Dec. 23, 2013	Jul. 18, 2012
Business Acquisition
Goodwill	$53,196,000	$18,372,000
In process research and development, cost to complete	14,100,000
Acquisition 2014
Business Acquisition
Payments to Acquire Businesses, Gross	36,128,000
Range of aggregate undiscounted contingent consideration from acquisitions, maximum	15,000,000		15,000,000
Net assets acquired			47,428,000
Goodwill			34,824,000
Acquisition 2013
Business Acquisition
Range of aggregate undiscounted contingent consideration from acquisitions, maximum				14,300,000
Net assets acquired				16,775,000
Goodwill				2,999,000
Acquisition 2012
Business Acquisition
Net assets acquired					6,031,000
Goodwill					$5,564,000
Minimum | In-process Research and Development
Business Acquisition
Pre tax royalty rate	4.00%
Discount rate	13.50%
Maximum | In-process Research and Development
Business Acquisition
Pre tax royalty rate	9.00%
Discount rate	19.00%

ACQUISTIONS_Assets_Acquired_an

ACQUISTIONS (Assets Acquired and Liabilities) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Oct. 23, 2014		Dec. 23, 2013		Jul. 18, 2012
Business Acquisition
Goodwill	$53,196	$18,372
Acquisition 2014
Business Acquisition
Payments to Acquire Businesses, Gross	36,128
Inventory			9,599
Accounts receivable			1,529
Equipment			518
Trade Names			300
Other assets			292
Accounts payable and accrued expenses			-5,034
Contingent consideration			-11,300	[1]
Business Combination, Consideration Transferred	47,428
Total identifiable net assets			12,604
Goodwill			34,824
Net assets acquired			47,428
Acquisition 2013
Business Acquisition
Contingent consideration					-6,704	[2]
Total identifiable net assets					13,776
Goodwill					2,999
Net assets acquired					16,775
Acquisition 2012
Business Acquisition
Inventory							158
Contingent consideration							-2,311
Total identifiable net assets							467
Goodwill							5,564
Net assets acquired							6,031
In-process Research and Development | Acquisition 2013
Business Acquisition
Identifiable intangible assets:					20,460
Customer Relationships | Acquisition 2014
Business Acquisition
Identifiable intangible assets:			1,600
Customer Relationships | Acquisition 2012
Business Acquisition
Identifiable intangible assets:							120
Non-compete Agreements | Acquisition 2013
Business Acquisition
Identifiable intangible assets:					20
Non-compete Agreements | Acquisition 2012
Business Acquisition
Identifiable intangible assets:							80
Patents | Acquisition 2012
Business Acquisition
Identifiable intangible assets:							2,420
Supplier Network | Acquisition 2014
Business Acquisition
Identifiable intangible assets:			$3,800
[1]	The contingent consideration relates to the achievement of certain sales milestones. As of December 31, 2014, the aggregate, undiscounted amount of contingent consideration that we could pay related to the acquisitions ranges from zero to $15.0 million (see bNote 5. Fair Value Measurementsb below).
[2]	The contingent consideration relates to the achievement of certain regulatory milestones and royalties. As of December 31, 2013, the aggregate, undiscounted amount of contingent consideration that we could pay related to the acquisitions ranged from zero to $14.3 million (see bNote 5. Fair Value Measurementsb below).

ACQUISTIONS_Contingent_Conside

ACQUISTIONS (Contingent Consideration Payment Rollforward) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Contingent Consideration Payment [Roll Forward]
Business Combination, Contingent Consideration, Liability	$14,177	$7,358
Purchase price contingent consideration	11,300	6,704
Contingent payments	-11	-5
Changes in fair value of contingent consideration classified in operating expenses	-1,131	120
Business Combination, Contingent Consideration, Liability	$24,335	$14,177

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Acquired Intangible Assets
Intangible Assets, Gross Carrying Amount	$36,305	$30,603
Accumulated Amortization	-1,776	-1,066
Intangible asset amortization expense	710	528	468
Intangible assets, net	34,529	29,537
Finite-lived intangible assets, net	9,969
Supplier Network
Acquired Intangible Assets
Weighted average amortization period	10 years
Gross carrying amount	3,800
Accumulated Amortization	-88
Finite-lived intangible assets, net	3,712
Customer relationships & other intangibles
Acquired Intangible Assets
Weighted average amortization period	7 years 3 months	9 years 6 months
Gross carrying amount	5,525	3,623
Accumulated Amortization	-1,344	-864
Finite-lived intangible assets, net	4,181	2,759
Patents
Acquired Intangible Assets
Weighted average amortization period	17 years	17 years
Gross carrying amount	2,420	2,420
Accumulated Amortization	-344	-202
Finite-lived intangible assets, net	2,076	2,218
In-process Research and Development
Acquired Intangible Assets
Indefinite-lived intangible assets	$24,560	$24,560

INTANGIBLE_ASSETS_Expected_Fut

INTANGIBLE ASSETS Expected Future Amortization of Acquired Intangible Assets (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Year ending December 31, 2015	$1,545
Year ending December 31, 2016	1,541
Year ending December 31, 2017	1,423
Year ending December 30, 2018	856
Year ending December 31, 2019	852
Thereafter	3,752
Finite-lived intangible assets, net	$9,969

MARKETABLE_SECURITIES_Details

MARKETABLE SECURITIES (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Short-term Marketable Securities
Schedule of Marketable Securities
Amortized Cost	$146,467	$148,950
Gross Unrealized Gains	17	38
Gross Unrealized Losses	-45	-26
Fair Value	146,439	148,962
Short-term Marketable Securities | Municipal Bonds
Schedule of Marketable Securities
Amortized Cost	28,684	77,342
Gross Unrealized Gains	2	17
Gross Unrealized Losses	-3	-15
Fair Value	28,683	77,344
Short-term Marketable Securities | Municipal Bonds | Maximum
Schedule of Marketable Securities
Available For Sale Securities Contractual Maturity	1 year	1 year
Short-term Marketable Securities | Corporate Debt Securities
Schedule of Marketable Securities
Amortized Cost	73,066	35,525
Gross Unrealized Gains	7	15
Gross Unrealized Losses	-42	-11
Fair Value	73,031	35,529
Short-term Marketable Securities | Corporate Debt Securities | Maximum
Schedule of Marketable Securities
Available For Sale Securities Contractual Maturity	1 year	1 year
Short-term Marketable Securities | Commercial Paper
Schedule of Marketable Securities
Amortized Cost	44,663	36,083
Gross Unrealized Gains	8	6
Gross Unrealized Losses	0	0
Fair Value	44,671	36,089
Short-term Marketable Securities | Commercial Paper | Maximum
Schedule of Marketable Securities
Available For Sale Securities Contractual Maturity	1 year	1 year
Short-term Marketable Securities | Asset-backed Securities
Schedule of Marketable Securities
Amortized Cost	54
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	54
Short-term Marketable Securities | Asset-backed Securities | Maximum
Schedule of Marketable Securities
Available For Sale Securities Contractual Maturity	1 year
Long-term Marketable Securities
Schedule of Marketable Securities
Amortized Cost	75,422	36,488
Gross Unrealized Gains	7	42
Gross Unrealized Losses	-82	-2
Fair Value	75,347	36,528
Long-term Marketable Securities | Municipal Bonds
Schedule of Marketable Securities
Amortized Cost	26,005	12,304
Gross Unrealized Gains	3	13
Gross Unrealized Losses	-36	-1
Fair Value	25,972	12,316
Long-term Marketable Securities | Municipal Bonds | Minimum
Schedule of Marketable Securities
Available For Sale Securities Contractual Maturity	1 year	1 year
Long-term Marketable Securities | Municipal Bonds | Maximum
Schedule of Marketable Securities
Available For Sale Securities Contractual Maturity	2 years	2 years
Long-term Marketable Securities | Corporate Debt Securities
Schedule of Marketable Securities
Amortized Cost	19,617	17,533
Gross Unrealized Gains	3	27
Gross Unrealized Losses	-22	0
Fair Value	19,598	17,560
Long-term Marketable Securities | Corporate Debt Securities | Minimum
Schedule of Marketable Securities
Available For Sale Securities Contractual Maturity	1 year	1 year
Long-term Marketable Securities | Corporate Debt Securities | Maximum
Schedule of Marketable Securities
Available For Sale Securities Contractual Maturity	2 years	2 years
Long-term Marketable Securities | Asset-backed Securities
Schedule of Marketable Securities
Amortized Cost	21,236	6,651
Gross Unrealized Gains	1	2
Gross Unrealized Losses	-8	-1
Fair Value	21,229	6,652
Long-term Marketable Securities | Asset-backed Securities | Minimum
Schedule of Marketable Securities
Available For Sale Securities Contractual Maturity	1 year	1 year
Long-term Marketable Securities | Asset-backed Securities | Maximum
Schedule of Marketable Securities
Available For Sale Securities Contractual Maturity	2 years	2 years
Long-term Marketable Securities | US Government-sponsored Enterprises Debt Securities [Member]
Schedule of Marketable Securities
Amortized Cost	8,564
Gross Unrealized Gains	0
Gross Unrealized Losses	-16
Fair Value	$8,548

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Minimum | Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis
Discount rate	3.10%
Maximum | Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis
Discount rate	13.50%
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring Basis
Cash equivalents	9,802	$20,363
Contingent consideration	24,335	14,177
Fair Value, Measurements, Recurring | Municipal Bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	54,655	89,660
Fair Value, Measurements, Recurring | Corporate Debt Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	92,629	53,089
Fair Value, Measurements, Recurring | Commercial Paper
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	44,671	36,089
Fair Value, Measurements, Recurring | Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	21,283	6,652
Fair Value, Measurements, Recurring | US Government-sponsored Enterprises Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	8,548
Fair Value, Measurements, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis
Cash equivalents	1,302	800
Contingent consideration	0	0
Fair Value, Measurements, Recurring | Level 1 | Municipal Bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	0	0
Fair Value, Measurements, Recurring | Level 1 | Corporate Debt Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	0	0
Fair Value, Measurements, Recurring | Level 1 | Commercial Paper
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	0	0
Fair Value, Measurements, Recurring | Level 1 | Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	0	0
Fair Value, Measurements, Recurring | Level 1 | US Government-sponsored Enterprises Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	0
Fair Value, Measurements, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis
Cash equivalents	8,500	19,563
Contingent consideration	0	0
Fair Value, Measurements, Recurring | Level 2 | Municipal Bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	54,655	89,660
Fair Value, Measurements, Recurring | Level 2 | Corporate Debt Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	92,629	53,089
Fair Value, Measurements, Recurring | Level 2 | Commercial Paper
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	44,671	36,089
Fair Value, Measurements, Recurring | Level 2 | Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	21,283	6,652
Fair Value, Measurements, Recurring | Level 2 | US Government-sponsored Enterprises Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	8,548
Fair Value, Measurements, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis
Cash equivalents	0	0
Contingent consideration	24,335	14,177
Fair Value, Measurements, Recurring | Level 3 | Municipal Bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	0	0
Fair Value, Measurements, Recurring | Level 3 | Corporate Debt Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	0	0
Fair Value, Measurements, Recurring | Level 3 | Commercial Paper
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	0	0
Fair Value, Measurements, Recurring | Level 3 | Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	0	0
Fair Value, Measurements, Recurring | Level 3 | US Government-sponsored Enterprises Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities, Fair Value	0

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$8,847	$1,369
Work in process	2,490	2,820
Finished goods	79,608	66,161
Total	$90,945	$70,350

PROPERTY_EQUIPMENT_Details

PROPERTY & EQUIPMENT (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property and Equipment
Depreciation	$21,044	$18,869	$17,640
Property and equipment, gross	188,019	164,060
Less: accumulated depreciation	-118,544	-99,910
Total	69,475	64,150
Land
Property and Equipment
Property and equipment, gross	4,116	3,769
Building and improvements
Property and Equipment
Useful Life	30 years
Property and equipment, gross	10,369	9,541
Equipment
Property and Equipment
Property and equipment, gross	17,783	14,588
Equipment | Minimum
Property and Equipment
Useful Life	5 years
Equipment | Maximum
Property and Equipment
Useful Life	7 years
Instruments
Property and Equipment
Useful Life	3 years
Property and equipment, gross	123,864	107,867
Modules and cases
Property and Equipment
Useful Life	3 years
Property and equipment, gross	25,155	22,325
Other property and equipment
Property and Equipment
Property and equipment, gross	$6,732	$5,970
Other property and equipment | Minimum
Property and Equipment
Useful Life	3 years
Other property and equipment | Maximum
Property and Equipment
Useful Life	5 years

ACCRUED_EXPENSES_Details

ACCRUED EXPENSES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Compensation and other employee-related costs	$19,933	$17,428
Legal and other settlements and expenses	27,686	23,765
Accrued non-income taxes	4,720	2,938
Other	9,160	6,994
Total accrued expenses	$61,499	$51,125

DEBT_Details

DEBT (Details) (Revolving Credit Facility, USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Debt Instruments
Credit facility, current borrowing capacity	$50
Credit facility, maximum borrowing capacity	75
Revolving credit facility, minimum termination notice period	10 days
Fluctuating Rate Per Annum
Debt Instruments
Credit facility, basis spread on variable rate	0.75%
Credit facility, variable rate	LIBOR
Credit facility, period of variable rate	1 month
Fixed Rate
Debt Instruments
Credit facility, basis spread on variable rate	0.75%
Credit facility, variable rate	LIBOR
Fixed Rate | Minimum
Debt Instruments
Credit facility, period of variable rate	1 month
Fixed Rate | Maximum
Debt Instruments
Credit facility, period of variable rate	3 months
Letter of Credit
Debt Instruments
Credit facility, maximum borrowing capacity	$25

EQUITY_Textuals_Details

EQUITY (Textuals) (Details) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Aug. 31, 2012	Aug. 03, 2012
Class of Stock
Common stock, shares outstanding	94,705,743	93,442,753
Gross proceeds from issuance initial public offering			$25,000,000
Proceeds From Issuance Initial Public Offering, Net of Underwriting Fees and Offering Expenses	0	0	20,960,000
Net proceeds from issuance of common stock	$9,738,000	$7,555,000	$1,504,000
Class A Common
Class of Stock
Common stock, shares outstanding	70,828,187	66,065,197
Offering price per share (in usd per share)					$12
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, votes per share	1
Class B Common
Class of Stock
Common stock, shares outstanding	23,877,556	27,377,556
Common stock, shares authorized (in shares)	275,000,000	275,000,000
Common stock, votes per share	10
Class C Common
Class of Stock
Common stock, shares authorized (in shares)	10,000,000
Issued by Company | Class A Common
Class of Stock
Shares sold for initial public offering (in shares)				2,083,333
Conversion of Class E to Class B
Class of Stock
Conversion of stock, shares converted				15,597,300
Conversion of Class B to Class A
Class of Stock
Conversion of stock, requirements, maximum ownership percentage				10.00%
Conversion of Class C to Class A
Class of Stock
Conversion of stock, shares converted				73,554
Conversion of Class B to Class A, Selling Stockholders
Class of Stock
Conversion of stock, shares converted				3,039,385
Equity Ownership of Less Than Ten Percent | Conversion of Class B to Class A
Class of Stock
Conversion of stock, shares converted				49,655,411

EQUITY_Schedule_of_Issued_and_

EQUITY (Schedule of Issued and Outstanding Shares) (Details)	Dec. 31, 2014	Dec. 31, 2013
Class of Stock
Common stock, shares outstanding	94,705,743	93,442,753
Common stock, shares issued	94,705,743	93,442,753
Class A Common
Class of Stock
Common stock, shares outstanding	70,828,187	66,065,197
Common stock, shares issued	70,828,187	66,065,197
Class B Common
Class of Stock
Common stock, shares outstanding	23,877,556	27,377,556
Common stock, shares issued	23,877,556	27,377,556

STOCKBASED_COMPENSATION_Textua

STOCK-BASED COMPENSATION (Textuals) (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation, Number of Stock Plans	3
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Maximum contractual term	10 years
Award vesting period (in years)	4 years
Unrecognized compensation expense, unvested stock options	$16.10
Weighted average period of recognition, unvested stock options	3 years
2012 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award
Base number of shares that may be issuable under stock plan	3,076,923
2012 Equity Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares available for grant	10,769,230
Annual percentage limit for incremental shares that may be issued	3.00%
2012 Equity Incentive Plan | Class A Common
Share-based Compensation Arrangement by Share-based Payment Award
Shares reserved under the 2012 Equity Incentive Plan	9,085,832
Number of shares available for grant	6,019,966
Original Fair Value of Common Stock | February 2, 2012 Grant
Share-based Compensation Arrangement by Share-based Payment Award
Exercise price per share granted		$10.34

STOCKBASED_COMPENSATION_Grant_

STOCK-BASED COMPENSATION (Grant Date Fair Values of Options Awarded to Employees) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant date per share fair value	$9.63	$6.34	$5.90

STOCKBASED_COMPENSATION_Fair_V

STOCK-BASED COMPENSATION (Fair Value of Options, Assumptions) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Risk-free interest rate, minimum	1.51%	0.98%	0.90%
Risk-free interest rate, maximum	1.95%	1.74%	1.10%
Expected volatility, minimum	35.00%	41.00%	44.00%
Expected volatility, maximum	41.00%	44.00%	47.00%
Expected term			6 years
Expected dividend yield	0.00%	0.00%	0.00%
Minimum
Expected term	5 years 3 months 22 days	6 years 0 months 28 days
Maximum
Expected term	6 years 4 months 16 days	6 years 4 months 16 days

STOCKBASED_COMPENSATION_Stock_

STOCK-BASED COMPENSATION (Stock Option Activity) (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares outstanding beginning balance	4,886	6,253	6,454
Number of shares granted	1,495	1,222	1,228
Number of shares exercised	-1,263	-2,173	-1,061
Number of shares forfeited	-264	-416	-368
Number of shares outstanding ending balance	4,854	4,886	6,253
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average exercise price per share outstanding beginning balance	$10.04	$6.99	$5.14
Weighted average exercise price per share granted	$23.45	$14.78	$13.10
Weighted average exercise price per share exercised	$7.71	$3.48	$1.42
Weighted average exercise price per share forfeited	$15.33	$12.23	$9.55
Weighted average exercise price per share outstanding ending balance	$14.50	$10.04	$6.99
Number of shares exercisable	2,390
Weighted average exercise price per share exercisable	$9.08
Weighted average remaining contractual life outstanding	7 years 1 month 6 days
Weighted average remaining contractual life exercisable	5 years 4 months 24 days
Aggregate intrinsic value outstanding	$45,731
Aggregate intrinsic value exercisable	35,093
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	2,464
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$19.76
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	8 years 9 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$10,638

STOCKBASED_COMPENSATION_Compen

STOCK-BASED COMPENSATION (Compensation Expense Related to Stock Options and Their Intrinsic Values) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Compensation expense related to stock options	$7,111	$5,177	$4,635
Intrinsic value of stock options exercised	$20,216	$25,034	$12,507

INCOME_TAXES_Components_of_Inc

INCOME TAXES (Components of Income (Loss) Before Income Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Income before taxes, domestic	$137,643	$101,424	$114,176
Income/(loss) before taxes, foreign	999	577	477
Income before income taxes	$138,642	$102,001	$114,653

INCOME_TAXES_Components_of_Pro

INCOME TAXES (Components of Provision for Income Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current Income Tax Expense
Current income tax provision, federal	$43,561	$41,741	$40,338
Current income tax provision, state	6,097	6,118	6,419
Current income tax provision, foreign	519	912	345
Current income tax provision	50,177	48,771	47,102
Deferred Income Tax Expense/(Benefit)
Deferred income tax provision/(benefit), federal	-3,630	-14,088	-5,510
Deferred income tax (benefit), state	-357	-1,210	-352
Deferred income tax provision/(benefit), foreign	-33	-84	-418
Deferred income tax provision/(benefit)	-4,020	-15,382	-6,280
Income tax provision, total	$46,157	$33,389	$40,822

INCOME_TAXES_Reconciliation_of

INCOME TAXES (Reconciliation of Statutory U.S. Federal Tax Rate to Effective Rate) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Statutory U.S. federal tax rate	35.00%	35.00%	35.00%
State income taxes, net of federal benefit	2.60%	2.80%	2.90%
Domestic production activities deduction	-2.70%	-3.50%	-2.30%
Tax credits	-1.20%	-1.70%	-0.10%
Nondeductible expenses	0.70%	1.70%	1.40%
Other	-1.10%	-1.60%	-1.30%
Effective tax rate	33.30%	32.70%	35.60%

INCOME_TAXES_Components_of_Def

INCOME TAXES (Components of Deferred Income Taxes) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Components of Deferred Tax Assets [Abstract]
Inventory reserve	$22,808	$19,635
Accruals, reserves, and other currently not deductible	19,043	17,133
Stock-based compensation	5,548	5,152
Foreign net operating loss carryforwards	418	724
Total deferred tax assets	47,817	42,644
Valuation allowance	-45	-327
Total deferred tax assets, net of valuation allowance	47,772	42,317
Components of Deferred Tax Liabilities [Abstract]
Depreciation and amortization	-9,865	-9,759
Other	-2,643	-1,229
Total deferred tax liabilities	-12,508	-10,988
Net deferred tax assets	$35,264	$31,329

INCOME_TAXES_Reconciliation_of1

INCOME TAXES (Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits at the beginning of the year	$3,978	$3,500	$2,799
Additions related to current year tax positions	0	661	673
Additions related to prior year tax positions	614	64	46
Reductions related to prior year tax positions	-209	-109	-18
Lapse of statute of limitations	-202	-138	0
Settlements	-953	0	0
Unrecognized tax benefit at the end of the year	3,228	3,978	3,500
Portion of total unrecognized tax benefits that, if recognized, that would affect the effective income tax rate	$838	$1,184	$747

INCOME_TAXES_Narrative_Details

INCOME TAXES (Narrative) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Income Tax Examination
Benefit recorded in 2013 for reinstated 2012 tax credit		$0.90
Other Assets
Income Tax Examination
Long term deferred tax asset	$0.40	$0.40

LEASES_Minimum_Future_Rental_P

LEASES (Minimum Future Rental Payments Under Operating Leases) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Leases, Operating [Abstract]
Year ending December 31, 2015	$700
Year ending December 31, 2016	546
Year ending December 31, 2017	279
Year ending December 31, 2018	105
Year ending December 31, 2019	0
Thereafter	0
Total	$1,630

LEASES_Rent_Expense_Related_to

LEASES (Rent Expense Related to Operating Leases) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Leases, Operating [Abstract]
Rent expense	$676	$424	$419

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	12 Months Ended			3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2014	Jul. 31, 2011	Oct. 31, 2010
					claim	claim
Loss Contingencies
Provision for litigation litigation loss/(income)	$5,667,000	$23,055,000	($786,000)
Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation
Loss Contingencies
Damages awarded		16,000,000
Patent claims (number of claims)					3
Combined litigation loss		19,500,000
Provision for litigation loss - cost of goods sold		1,300,000
Provision for litigation litigation loss/(income)	600,000	18,200,000
NuVasive, Inc
Loss Contingencies
Patent claims (number of claims)						3
Bianco
Loss Contingencies
Combined litigation loss		4,300,000
Royalty Rate	5.00%
Altus Partners, LLC
Loss Contingencies
Provision for litigation litigation loss/(income)				$2,000,000
Minimum | Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation
Loss Contingencies
Patent claims (number of claims)	1
Minimum | NuVasive, Inc
Loss Contingencies
Patent claims (number of claims)						1

RETIREMENT_BENEFIT_PLANS_Detai

RETIREMENT BENEFIT PLANS (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]
Nondiscretionary employee contribution match rate	100.00%
Maximum annual contribution match, per employee	$6,000
Maximum annual contribution match, percent per employee	3.00%
401(k) and other retirement plan contributions	$2,185,000	$2,106,000	$1,055,000

RELATEDPARTY_TRANSACTIONS_Deta

RELATED-PARTY TRANSACTIONS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Related Party Transactions [Abstract]
Accounts payable to related-party	$5,359	$2,656
Purchases from related-party supplier	$21,948	$20,039	$20,159

SEGMENT_AND_GEOGRAPHIC_INFORMA2

SEGMENT AND GEOGRAPHIC INFORMATION (Geographic Location) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
									segments
Revenues from External Customers
Number of reportable segments									1
Total sales	$128,801	$117,787	$113,573	$114,210	$115,245	$107,187	$107,009	$105,018	$474,371	$434,459	$385,994
United States
Revenues from External Customers
Total sales									427,091	396,615	355,609
International
Revenues from External Customers
Total sales									$47,280	$37,844	$30,385

SEGMENT_AND_GEOGRAPHIC_INFORMA3

SEGMENT AND GEOGRAPHIC INFORMATION (Products) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
									segments
									categories
Revenue from External Customer
Total sales	$128,801	$117,787	$113,573	$114,210	$115,245	$107,187	$107,009	$105,018	$474,371	$434,459	$385,994
Textuals [Abstract]
Number of reportable segments									1
Number of product categories									2
Innovative Fusion
Revenue from External Customer
Total sales									270,852	254,033	238,723
Disruptive Technology
Revenue from External Customer
Total sales									$203,519	$180,426	$147,271

QUARTERLY_FINANCIAL_DATA_unaud2

QUARTERLY FINANCIAL DATA (unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Sales	$128,801	$117,787	$113,573	$114,210	$115,245	$107,187	$107,009	$105,018	$474,371	$434,459	$385,994
Gross Profit	97,525	90,101	86,990	88,898	88,471	81,872	82,248	81,525	363,514	334,116	310,795
Net income	$27,638	$23,061	$20,647	$21,139	$20,985	$20,310	$7,426	$19,891	$92,485	$68,612	$73,831
Net earnings per common share - basic	$0.29	$0.24	$0.22	$0.23	$0.22	$0.22	$0.08	$0.22	$0.98	$0.74	$0.82
Net earnings per common share - dilutive	$0.29	$0.24	$0.22	$0.22	$0.22	$0.22	$0.08	$0.21	$0.97	$0.73	$0.80

SUBSEQUENT_EVENT_Details

SUBSEQUENT EVENT (Details) (Subsequent Event, USD $)	0 Months Ended
In Thousands, unless otherwise specified	Feb. 25, 2015
Subsequent Event
Subsequent Event
Payments to Acquire Businesses, Gross	$52,900

VALUATION_ACCOUNTS_AND_QUALIFY2

VALUATION ACCOUNTS AND QUALIFYING ACCOUNTS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for doubtful accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning of period	$1,581	$961	$602
Additions	318	693	363
Write-offs	-252	-73	-4
End of period	1,647	1,581	961
Deferred tax valuation allowance
Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning of period	327	533	1,149
Additions	0	0	0
Write-offs	-282	-206	-616
End of period	$45	$327	$533